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 Although the etiology of a particular disease will vary, there are genetic and epigenetic 
bottlenecks that frequently converge resulting in dysregulation of mitogenic and morphogenetic 
signaling. This propensity is acutely experienced in malignancy and neurodegenerative disease.  
Here, we have first investigated the role of dysregulated signaling in the context of 
pancreatic cancer (PC). Morphogenetic signaling has been regarded as a pleiotropic pathway 
with the potential to promote and inhibit metastatic features. Our investigation of bone 
morphogenetic protein 2 (BMP-2), an archetypical member of the BMP superfamily, has 
revealed the presence of extracellular, intracellular, and long non-coding RNA products. Our 
findings implicate the individual product activity as significant determining factors in the 
functional output. Although our observations suggest a novel explanation for these pleiotropic 
properties, futures studies will be necessary to understand how these variants may behave from 
an in vivo perspective. 
Next, we have examined how this axis is exploited in Alzheimer’s disease (AD). AD is 
characterized by progressive neurodegeneration. The most frequently implicated feature 
associated with AD is the pathological accumulation of the amyloid beta (Aβ) peptide. While the 
extracellular deposition of Aβ is thought to be the pathophysiological form, recent findings have 
shown that intracellular expression of Aβ precedes the extracellular deposition. This observation 
suggests the intracellular localization of the Aβ peptide may harbor important and unknown 
pathophysiological properties. To address the influence of intracellular Aβ on neurotrophin 
mediated mitogen signaling and BMP-2 mediated morphogen signaling we have employed a 
cell line model (HEK293 and primary rat hippocampal neurons). Interestingly, our investigation 
has revealed an intracellular Aβ dependent decrease in mitogen signaling intensity and increase 
in BMP-2 signaling. Combined, this pattern of dysregulation is closely mirrored during 
embryonic and postnatal programmed cell death. Further studies will need to be performed to 
assess how these finding may behave in an in vivo setting. 
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1.1 Role of Mitogen and Morphogen Signaling Dysregulation in Pancreatic cancer 
 
1.1.1 Molecular and Genetic Features of Pancreatic Cancer 
From a histological standpoint, PC progression is represented as the advancement of 
pre-neoplastic lesions (pancreatic intra-epithelial neoplasias: PanIN-I, PanIN-2, and PanIN-3) 
that gradually acquire an increasing number of morphological and genetic changes ultimately 
leading to development of pancreatic ductal adenocarcinoma (PDAC). Foremost in the acquired 
molecular/genetic alterations, are the presence of enhanced epidermal growth factor receptor 
(EGFR) signaling, point mutations affecting K-Ras, inactivating p53 mutations, and mutations 
involving the bone morphogenetic superfamily signaling pathways (i.e. DPC4/Smad 4).  
Amplifications and activating mutations of the receptor tyrosine kinase EGFR (ErbB1) 
are both early and prominent genetic alterations observed in PC (Lee, Jang et al. 2007, Faller, 
Burtness 2009). Moreover, the corresponding activation of the MAPK cascade is integral for 
subsequent initiation and progression of PC (Ardito, Gruner et al. 2012, Navas, Hernandez-
Porras et al. 2012). While the overall contributions these changes in EGFR activity may 
contribute to PC are undoubtedly significant, acinar to ductal metaplasia (ADM) has been shown 
to be influenced by the presence or absence of these variations in EGFR activity. The process 
of ADM, wherein, acinar cells undergo transdifferentiation to ductal cells are considered to be an 
early pathophysiological change in the progression to PDAC. Indeed, in genetically engineered 
mouse models harboring acinar cell specific expression of the constitutively active K-Ras G12V 
with intact EGFR expression showed low-grade PanIN lesions, high-grade PanIN lesions, and 
PDAC. However, when constitutively active K-RasG12V was expressed in the context of EGFR 
deletion, these mice showed a marked reduction in the number and grade of PanIN lesions with 
no PDAC seen (Navas, Hernandez-Porras et al. 2012). Indeed, these observations suggest a 
potentially important role of EGFR activity in the induction and progression PC. While EGFR 
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amplifications and activating mutations make significant contributions to disease initiation and 
progression, activating K-Ras mutations are an equally essential feature in the majority of PDAC 
cases. Mutations in K-Ras, a downstream effector of numerous growth factor signaling 
pathways, affects the GTPase domain of this protein resulting in constitutive activity that is 
known to alter a number of effector pathways shown to be integral to the regulation of cell 
survival and cell proliferation (Aguirre, Bardeesy et al. 2003). Thus, the combination of increased 
EGFR activity and constitutively active K-RasMut leads to subsequent induction of downstream 
signaling (i.e. via Raf/Mek/Erk) and subsequent oncogenic transcriptional programs. 
Another molecular aberration regularly encountered in the course of PC progression is 
the inactivation of the tumor suppressor protein p53. Point missense mutations in the DNA 
binding domain of this protein mitigates the tumor suppressive restraints thereby promoting 
invasiveness, cell proliferation, and may serve to foster further genetic instability (Muller, 
Vousden 2013, Aguirre, Bardeesy et al. 2003). When employed in genetically engineered 
mouse models, the signature genetic alteration involving K-Ras and p53 accurately mirror the 
histopathological and molecular events that surround PC progression and are invaluable tools in 
the study of this aggressive disease (Hezel, Kimmelman et al. 2006, Aguirre, Bardeesy et al. 
2003).  
While the complexity of the molecular and genetic changes incurred during PC are 
inherently heterogeneous, mutations involving the DPC4/Smad 4 (Smad 4) are commonly 
encountered alterations found in the latter stages of PC progression. The common mediator 
Smad 4 is an integral component in the bone morphogenetic super-family (bone morphogenetic 
proteins (BMP), activin, nodal, and growth and differentiation factors (GDFs), and transforming 
growth factor β (TGFβ)) signaling pathway. These proteins have shown themselves to be pivotal 
regulators of cellular proliferation, differentiation, and motility (Wrana 2013, Weiss, Attisano 
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2013a).  While numerous BMP super-family members play a role in PC, our work has focused 
on BMP-2 mediated signal transduction as a model for this category of signaling.  
1.1.2 Bone Morphogenetic Protein-2 Signaling 
The BMP-2 ligand is initially translated as an inactive precursor protein dependent upon 
entry into the secretory pathway for subsequent proteolytic cleavage by furin-like protease to 
achieve their bioactive state. Following cleavage, they undergo dimerization and are secreted 
into the extracellular compartment to initiate autocrine /paracrine signaling (Heng, Paule et al. 
2010). Subsequent, morphogen signaling is initiated through binding of the dimerized ligand to 
type I and type II serine/threonine kinase receptors. The formation of this hetero-oligomeric 
complex allows signal transduction to occur via intracellular phosphorylation of receptor-Smads 
(R-Smads). Once phosphorylated, R-smads 1/5/8 form heteromeric complexes with common 
mediator-Smad (Smad 4) leading to their accumulation in the nucleus (Wrana 2013). Following 
this nuclear enrichment, these Smad complexes are targeted to Smad binding elements (SBE). 
Subsequently, depending upon their association with transcription factors and co-factors, they 
serve as enhancers or inhibitors of expression thereby enabling extracellular cues to alter the 
transcriptional profile of the cell (Massague 2012). 
Though canonical extracellular BMP-2 dependent activation of morphogen signaling has 
been implicated as the principle biological and pathophysiological mediator, an intracellular 
isoform has also been identified. Owing to the utilization of an alternative downstream 
translational initiation site, an alternative reading frame is employed that produces a truncated 
protein with intracellular localization (Felin, Mayo et al. 2010). Analogous to alternative splicing, 
the utilization of an alternative reading frame is recognized as a commonly employed 
mechanism to diversify the function and localization of a gene product. Whether through the 
presence of an IRES (internal ribosomal entry site), leaky scanning, or other mechanisms, 
isoform production through utilization of alternative translational initiation sites are important 
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facets of normal and cancer biology (Truitt, Ruggero 2016, Andrews, Rothnagel 2014). Although 
the functional implications of the intracellular isoform of BMP-2 has thus far been investigated in 
muscle and immune cells, the role in PC has yet to be explored (Bridgewater, Mayo et al. 2013, 
Olsen, Goar et al. 2015).  
In addition to protein coding gene outputs, the presence of long non-coding RNAs 
(lncRNA) are important participants within the cellular milieu. The contribution of intergenic non-
coding RNAs are being increasingly recognized for their biological and pathophysiological 
contributions. The functional diversity of lncRNA continues to grow and has been shown to 
harbor cis/trans, cytosolic/nuclear, intracellular/extracellular, cell autonomous/non-autonomous 
functions (Mercer, Mattick 2013, Wilusz, Freier et al. 2008, Kogure, Yan et al. 2013). 
Furthermore, the molecular associations that facilitate lncRNA function (i.e. RNA:DNA, 
RNA:RNA, and RNA:Protein) produces a wide array of changes to gene expression, protein 
localization, and function (Quinn, Chang 2016). In addition to the aforementioned coding 
isoforms of BMP-2, we have identified a novel BMP-2 splice variant with non-coding activity. 
Thus, BMP-2 dependent activation of the morphogenetic signaling pathway is dependent upon 
the cumulative expression profile consisting of extracellular, intracellular, and non-coding 
variants of the BMP-2 gene cassette. Moreover, expression of the various BMP-2 gene 
constituents may have particular relevance in the genetic background of PC.  
 
1.1.3 Molecular Crosstalk in Pancreatic Cancer 
 Intuitively, the transcriptional profile, mediated by K-Ras activation, p53 status, and 
Smad 4 integrity would suggest a natural cooperative influence on one another. However, the 
degree of interaction and crosstalk between these hallmark changes in PC are not only 
circuitous, but also directly influence the activities of each other. In particular, the mitogen and 
morphogen signaling pathways have been shown to reciprocally influence the activity of these 
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seemingly distinct pathways. Indeed, activation of the MAPK signaling pathway leads to an ERK 
1/2 mediated phosphorylation of serine residues present within the linker region of Smad 1 
(Guo, Wang 2009, Aubin, Davy et al. 2004). Consequently, this phosphorylation both impedes 
the cytoplasmic to nuclear shuttling necessary for Smad dependent transcriptional changes and 
leads to the recruitment of the ubiquitin ligase Smurf1 (SMAD Specific E3 Ubiquitin Protein 
Ligase 1)  (Zhu, Kavsak et al. 1999). Subsequently, polyubiquitination of lysine residues in the 
linker region of Smad 1 results in its proteasomal degradation. While, Smad proteins are directly 
influenced by MAPK signaling, morphogenetic signaling may also affect MAPK signaling activity 
through non-canonical mechanisms. Namely, the BMP-2 mediated activation of its respective 
serine/threonine kinase receptors leads to subsequent recruitment and activation of TAK1 
(Transforming growth factor beta-activated kinase 1) (Kishimoto, Matsumoto et al. 2000). In the 
context of cancer, activation of TAK1 can lead to the downstream activation of MAPKs to 
promote proliferation and stress response programs.  
 While there are numerous points of intersection involving the mitogen and morphogen 
signaling pathways, morphogenetic signaling is also strongly influenced by p53 status (Liu, Jia 
et al. 2013, Voorneveld, Kodach et al. 2015). For instance, in colorectal cancer Wnt signaling 
activation has been shown to be dependent upon loss of p53 and Smad 4 (Verheyen 2007). 
Moreover, the antagonistic activity of Smad signaling on Wnt activity relies upon the presence a 
wild-type p53 (Voorneveld, Kodach et al. 2015). In contrast, when p53 is mutated, the 
morphogenetic signaling leads to activation of pro-metastatic programs (Adorno, Cordenonsi et 
al. 2009). 
 The cumulative effects of constitutive K-Ras activation, p53 inactivation, and of Smad 4 
activity are firmly established molecular genetic features of PC. Furthermore, the context 
whereby morphogen signaling tends to be most acutely manifested in an oncogenic manner is 
when Smad signaling has been abrogated through negative regulation via MAPK signaling, loss 
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of p53, and through the loss of Smad 4 integrity. Although common in PC, loss of Smad 4 is still 
only present in a minority of samples suggesting an alternative means by which this branch of 
signaling may be dysregulated. Furthermore, a hallmark of the BMP superfamily is a 
characteristic pleiotropy observed in the context of cancer wherein the expression of these 
genes has both oncogenic and tumor-suppressive properties. Undoubtedly, the genetic 
background may play a significant role in the functional output resulting from morphogen 
signaling. However, it has yet to be determined how the expression of the various BMP-2 
products may contribute to the apparent pleiotropic activity observed in the context of BMP-2 
expression. We hypothesize that variable BMP-2 variant expression may contribute the 
pleiotropic features associated with this cytokine and thus affect mitogen and morphogen 
signaling homeostasis. 
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1.2 Role of Mitogen and Morphogen Signaling in Alzheimer ’s Disease 
 
1.2.1 Molecular Features of Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most frequently occurring neurodegenerative disorder in 
the United States with close to 13.8 million men and women 65 years and older projected to be 
diagnosed with this illness by the year 2050 (alz.org). Furthermore, while current estimates 
related to the care and treatment of those suffering from AD are close to $236 billion, the 
projected costs are expected to reach as high as $1 trillion by 2050 (alz.org). This astonishingly 
high prevalence and the socioeconomic expense of treating and caring for those suffering from 
AD demands that we investigate novel strategies to avert the impending catastrophic rise in its 
incidence and prevalence.  
It has been more than a century since the characteristic neuropathological features 
associated with AD was first identified by Alois Alzheimer (1907) (Allen 2007). However, while 
we have elucidated many of the etiological determinants of AD, the precise mechanism in which 
these changes elicit neurotoxicity remains poorly resolved. Foremost, the accumulation of 
extracellular amyloid beta positive plaques and hyperphosphorylated Tau positive neurofibrillary 
tangles have been most frequently tied to this illness. 
 Purification and identification of amino acid sequence of the amyloid beta peptide from 
brain tissue quickly led to identification of the parent molecule amyloid precursor protein (APP) 
(Goldgaber, Lerman et al. 1987, Glenner, Wong 1984). APP is a single-pass transmembrane 
protein, whose metabolism through the endoproteolytic activity of β-secretase and γ-secretase 
yield an amyloidogenic peptide (Citron, Oltersdorf et al. 1992). The byproduct of APP 
processing produces an extracellular protein fragment ranging from 36-42 amino acid in length 
(Allen 2007).  Furthermore, the inherent secondary structure and further tertiary organization 
and assembly of the extracellular amyloid beta into oligomers and fibrils is believed to contribute 
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to the characteristic deposition (Howland, Trusko et al. 1998, Kelly 1998). However, recent 
findings regarding the distribution of amyloid beta has revealed the localization of amyloid beta 
to be far more diverse than previously considered. 
 The most compelling evidence to suggest an alternative itinerary for amyloid beta is 
derived from in vivo analysis employing genetically engineered mouse models of AD. In 
particular, triple-transgenic (PS1M146V, TauP301L, APPSwe) mice were found to possess 
intracellular localization of the amyloid beta peptide (Hussein, Hashem et al. 2015). 
Furthermore, a post-mortem examination of patients with heritable early onset AD (EOAD) 
bearing mutations in the APP gene or amplifications of APP bearing chromosome 21 have 
similarly demonstrated amyloid beta to be localized both extracellularly and intracellularly 
(Oddo, Caccamo et al. 2003). Furthermore, the appearance and subsequent accumulation of 
intracellular amyloid beta peptide has been found to precede extracellular accumulation (Gyure, 
Durham et al. 2001). The intracellular spectrum of amyloid beta distribution has been shown to 
be remarkably varied and has been detected in association with endosomes, multivessicular 
bodies, lysosomal compartments, mitochondria, endoplasmic reticulum, and cytosolic 
expression (Lee, Park et al. 2006, LaFerla, Green et al. 2007, Baker-Nigh, Vahedi et al. 2015, 
Takahashi, Milner et al. 2002).  While no definitive mechanistic findings can explicitly describe 
the intracellular localization of amyloid beta peptide, recent work has identified the presenilin 2 
(PSEN2) mediated targeting of γ-secretase to late endosomes and lysosomes and subsequent 
metabolism of APP as a possible route for intracellularly metabolized amyloid beta peptide 
(Sannerud, Esselens et al. 2016). 
  
1.2.2 Mitogen Signaling in Alzheimer’s Disease 
Neurotrophins are a diverse family of growth factors and cytokines that play an integral 
role in maintaining and promoting neuronal differentiation, growth, and survival (Hempstead, 
Martin-Zanca et al. 1991). Foremost among this varied group of molecules are nerve growth 
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factor (NGF), brain-derived neurotrophic factor (BDNF) and EGF. These neurotrophic growth 
factors have been shown as necessary for maintaining and promoting the survival of neuronal 
populations found to be particularly sensitive to AD mediated neurodegenerative effects as seen 
in the cholinergic basal forebrain (CBF), hippocampus, and in the cerebral cortex (Ando, 
Kobayashi et al. 2002). Indeed, use of NGF-blocking antibodies or NGF knockout mice have 
been shown to produce progressive neurodegeneration that can be subsequently rescued with 
ectopic NGF treatment (Capsoni, Giannotta et al. 2002). Furthermore, decreased levels of the 
NGF receptor TrkA or BDNF and the BDNF receptor TrkB have also been found to be 
associated with the progression of AD mediated cognitive decline (Blasko, Lederer et al. 2006). 
Thus, an extensive degree of dysregulation of the neurotrophic activation of the MAPK signaling 
pathways is a common molecular consequence associated with the amyloid beta mediated 
effects observed in AD.  
 
1.2.3 Morphogenetic Signaling in Alzheimer’s Disease 
As compared to positive growth and survival cues mediated by mitogen signaling, the 
morphogenetic family of signaling molecules (i.e. BMP-2, BMP-4, TGFβ-1 &etc.) are crucial to 
promoting differentiation and induction of programmed cell death. For example, embryonic 
differentiation of the ectoderm into the CNS (central nervous system) and non-CNS cells rely 
extensively on the presence of gradients of BMPs. The expression of antagonists of BMPs (i.e. 
chordin, noggin, &etc.) leads to differentiation of the dorsal ectoderm into a neural cell fate. In 
contrast, expression of BMPs on the ventral side of the embryo leads to differentiation into non-
CNS tissue (Liu, Niswander 2005). Furthermore, BMPs have been shown to play critical roles in 
the induction of developmental interdigital apoptosis, and neural crest reorganization, and 
skeletal remodeling (Zou, Niswander 1996, Graham, Francis-West et al. 1994, Hay, Lemonnier 
et al. 2001).  
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While of critical significance in embryonic development, morphogen signaling also plays 
an important role in postnatal neuronal pruning and synaptic disassembly. The partial removal 
of synaptic formations and neuronal cells are necessary for establishing the adult neural 
network. This process of elimination is partly influenced by morphogen signaling (Low, Cheng 
2006). While we are born with approximately 100 billion neurons, as adults, the number can 
decrease by as much as 50% as a consequence of this large-scale remodeling (Bonora, 
Wieckowsk et al. 2015). Although neuronal programmed cell death is an integral feature of 
normal developmental biology, pathological dysregulation may play a role in AD.  
The pathophysiological significance of morphogen signaling may be dependent upon 
maintenance of an equilibrium of morphogen and mitogen signaling intensities. This delicate 
balance is influenced by several normal biological and pathophysiological circumstances. 
Indeed, the levels of BMPs and subsequent activation of Smad 1/5/8 signaling has been shown 
to increase in the hippocampus of aged brains leading to a subsequent decrease in 
neurogenesis (Yousef, Morgenthaler et al. 2015). In contrast, genetic ablation of Smad 1/5/8 
activity led to an increase in the abundance of neurogenesis. In addition to an age associated 
increase, BMP dependent Smad 1/5/8 phosphorylation, activation is also observed as a stress 
response during neuronal damage (Ueki, Reh 2012, Franke, Gubbe et al. 2006). Thus, while the 
increase in morphogen signaling may be a consequence of aging or activated in response to 
stress (i.e. oxidative, inflammatory, AD mediated), the functional output and consequences of 
this signaling my drastically and significantly depend on the context. Indeed, the necessity for 
this signaling homeostasis has been demonstrated using an in vitro model wherein BMP-2 or 
BMP-4 dependent Smad 1/5/8 phosphorylation has been shown to induce neurotrophic 
addiction in neural precursor cells (Gambaro, Aberdam et al. 2006, Pisano, Colon-Hastings et 
al. 2000). Thus, in the presence of morphogen signaling there is a greater reliance on positive 
mitogen reinforcement to maintain cell viability. 
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The extent to which intracellular amyloid beta may contribute to the coincidental 
dysregulation of both mitogen and morphogen signaling homeostasis has yet to be investigated. 
In the present study, we hypothesize that intracellular amyloid beta expression may lead to 
diminished mitogen signaling and an increase in morphogenetic sensitivity thereby perturbing 
the mitogen and morphogen signaling homeostasis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
CHAPTER 2 
 
The Characterization of the Bone Morphogenetic Protein 2 Gene Cassette Expression in 
Pancreatic Cancer 
 
 
Eric Cruz, Sushil Kumar, and Surinder K. Batra  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
Synopsis 
 
The bone morphogenetic protein (BMP) superfamily is a group of cytokines that have 
been long recognized to harbor context dependent oncogenic and tumor suppressive 
properties. This fundamental molecular pleiotropy has rendered targeting various aspects of this 
signaling modality, in the pathophysiological context of malignancy, ambiguous. In addition to 
the extracellular ligand, the presence of an intracellular isoform has also been identified. 
Furthermore, our investigation of the BMP-2 gene expression in pancreatic cancer has exposed 
a novel long non-coding transcript that is expressed in pancreatic cancer. Here, our 
investigation of the constituent variants of the BMP-2 gene (extracellular, intracellular, and non-
coding RNA) suggests the cumulative effects of the various products play a significant role 
affecting morphogenetic signal intensity and the oncogenic properties associated with BMP-2 
gene expression.   
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2.1 Introduction 
Pancreatic cancer (PC) is a deadly illness with a 5-year survival rate of only 7% 
(American Cancer Society 2016). While diagnostic and therapeutic challenges are an intrinsic 
feature of malignancy, there is a tragic and overwhelming manifestation of these obstacles in 
PC. Coupled to the absence of any overt early symptoms, physiological positioning of the 
pancreas deep within the abdominal cavity, and absence of reliable early detection methods has 
contributed to a diagnostic timeline that is often outside the therapeutic window. Furthermore, 
despite hallmark genetic aberrations (i.e. activating K-Ras & inactivating p53 mutations) in 
pancreatic cancer (PC), the inherent heterogeneity of this disease confers complex expression 
patterns that necessitates a subset based approach to identify new gene targets of potential 
diagnostic and therapeutic interest. Thus, to distinguish aberrantly expressed genes, we 
performed a meta-analysis on 11 COPA (Cancer Outlier Profile Analysis) transformed datasets 
(www.oncomine.org) depicting the transcriptional expression profiles of 416 pancreatic tumors.  
This analysis has revealed Bone Morphogenetic Protein 2 (BMP-2) to be significantly 
increased in a subset of PC tumor samples. Bone morphogenetic protein 2 is a representative 
member of a superfamily of evolutionarily conserved protein ligands to include activin, nodal, 
and growth and differentiation factors (GDFs), and transforming growth factor β (TGFβ) (Weiss, 
Attisano 2013b, Wakefield, Hill 2013). These cytokines are recognized as pivotal regulators of 
proliferation, motility, differentiation, & stem cell maintenance during embryonic development. 
Likewise, there is an increasing recognition of the role of BMPs in cancer progression and 
metastasis (Zhang, Chen et al. 2014, Jin, Pi et al. 2012).  
This ligand is initially translated as an inactive precursor protein whose maturation relies 
upon entry into the secretory pathway for subsequent proteolytic cleavage by furin-like 
proteases to render them bioactive. Following cleavage, they undergo dimerization and are 
secreted into the extracellular compartment to initiate autocrine /paracrine signaling (Heng, 
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Paule et al. 2010). Canonical BMP-2 signaling is mediated via type 1 & type 2 serine/threonine 
kinase receptors, which upon ligand binding, phosphorylate Smad proteins leading to their 
cytoplasmic/nuclear shuttling and induction of altered gene expression programs. This nuclear 
accumulation, influenced by the association with transcription factors, co-factors, and epigenetic 
state enables extracellular cues to alter the transcriptional profile of the cell in a context 
dependent manner (Massague 2012). 
In addition to the aforementioned molecular itinerary, BMP-2 has also been shown to 
use an alternative translational initiation site that produces a truncated and intracellular isoform 
of the protein (Felin, Mayo et al. 2010, Bridgewater, Mayo et al. 2013). While the intracellular 
BMP-2 has been most recently associated with immune response, we have further 
characterized the potential role of the intracellular isoform in the context of PC. Furthermore, our 
subsequent validation of the bioinformatics candidate BMP-2, has revealed a novel transcript of 
unknown coding potential (MacDonald, Ghosh 2006, Morris, Tomlins et al. 2008, Iyer, Niknafs et 
al. 2015). Intergenic non-coding RNAs are being increasingly recognized for their biological and 
pathophysiological contributions to malignant cell biology (Ranzani, Rossetti et al. 2015). 
Furthermore, given the molecular and genetic co-evolution of both coding and non-coding 
transcripts, there is a high probability for an overlapping function.  
Thus, to elucidate the role of BMP-2 gene cassette expression in morphogen signaling 
and functional changes associated with PC, we have employed both recombinant BMP-2 (i.e. 
mature extracellular BMP-2), the intracellular BMP-2 isoform, or the long non-coding RNA entity 
to biochemical and functionally assess the influence of each of the constituent members. Our 
data suggests that the oncogenic features of this gene are not strictly due to the canonical 
expression of the extracellular ligand, but rather a collective effect mediated by the expression 
of the extracellular coding and intracellular coding protein as well as the long non-coding 
expression of the BMP-2 gene cassette. This cumulative effect may be an important, and as of 
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yet unexplored, variable that imparts the seemingly pleiotropic features to the bone 
morphogenetic superfamily members. 
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2.2 Materials and Methods: 
2.2.1 Cell Culture, Transfections, and Transductions 
Transient and stable transfection was performed using Lipofectamine® 2000 transfection 
reagent. For stable selection of neomycin resistant transfectants, cells were treated for multiple 
passages with 700 µg/mL or 300 µg G418 (InvivoGen) containing DMEM (supplemented with 
10% FBS and 5% penicillin-streptomycin) for HEK293 and HupT3 cells respectively. Likewise, 
for the stable selection of puromycin resistant transfectants, cells were treated for multiple 
passages with 1 µg/mL puromycin containing DMEM (supplemented with 10% FBS and 100 
U/mL penicillin-streptomycin) for both HEK293 and HupT3 cells. Pooled clones were then grown 
in DMEM (supplemented with 10% FBS and 100 U/mL penicillin-streptomycin) and employed 
for subsequent treatment protocols. The various treatment protocols were performed in serum-
free DMEM for the lengths of time indicated unless otherwise indicated. 
2.2.2 Plasmids and Vector Cloning 
Cloning of the BSV expression vectors was accomplished by RT-PCR amplification from H1975 
derived cDNA, followed by cloning into PCR2.1 using the TOPO TA cloning Kit (Invitrogen). 
Subcloning was performed for subsequent cloning into p3xFLAG-CMV 10 vector (Sigma-
Aldrich). The long non-coding BSV was accomplished through cloning of the BSV sequence into 
the pBABE-puro vector without including the necessary Kozak sequence or translational start 
codon. Generation of the CRISPR/Cas9 targeting vectors was accomplished through the 
sgRNA design targeting upstream and downstream regions adjacent to the BMP-2 gene. 
Subsequently, cloning into the pSpCas9 BB-2A-GFP (PX458) and pSpCas9(BB)2APuro 
(PX459) vectors was performed. The Ikaros-CRISPR #2 (PX458-EF1a-pSpCas9(BB)-2A-GFP) 
was a gift from Ria Baumgrass (Addgene plasmid # 75241). Upon completion, all constructs 
were sequenced by the UNMC High-Throughput DNA Sequencing and Genotyping Core Facility 
to ensure proper composition. 
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2.2.3 Bioinformatics Analysis 
The study reviews 11 datasets recording gene expressions from prostate samples (for method 
validation) and 9 datasets (Badea, Herlea et al. 2008, Grutzmann, Pilarsky et al. 2004, 
Iacobuzio-Donahue, Maitra et al. 2003, Logsdon, Simeone et al. 2003, Segara, Biankin et al. 
2005, Buchholz, Kestler et al. 2005) from pancreatic sample data, with COPA analysis 
conducted  through the oncomine database (www.oncomine.org). Specifically, the COPA scores 
of each gene were calculated under each study. The 75th, 90th, and 95th percentiles of the COPA 
score are calculated for each gene before the genes are rank ordered by their percentile scores 
(i.e. 75th, 90th, 95th) for each of the datasets. We focus the analysis on the genes located at the 
top 100 rank with large 75th (or 90th or 95th) percentile of COPA scores. The genes were then 
tabulated to count the number of databases in which the gene is identified to be among the top 
100 of the ordered rank list based on any of the three percentiles (75th, 90th, and 95th). 
Consistent with previous reports, ERG and ETV1 were found to be particularly important genes 
for prostate cancer [35]. Gene selection in pancreatic cancer was performed through literature 
based review of identified candidates found to be ranked in the top 100 of the ordered gene list 
based percentile representation in multiple studies. Meta-COPA analysis was performed with 
the aid of Dr. Fang Yu from the UNMC College of Public Health Department of Biostatistics.  
2.2.4 Western Blotting 
Cells were lysed with RIPA buffer supplemented with cOmplete protease inhibitor cocktail 
(Roche), 8 mM sodium fluoride, 0.5 mM phenylmethylsulfonyl fluoride (PMFS), 1 mM sodium 
orthovanadate, and 2.5 mM sodium pyrophosphate. Protein was resolved through SDS-PAGE 
under denaturing conditions. Transfer on to polyvinylidene difluoride (PVDF) membrane was 
performed and blocked in 5% milk containing PBS or TBS. Subsequent incubation with the 
indicated antibody was done overnight at 4°C. Incubation with HRP-conjugated secondary in 
PBS or TBS containing 3% milk was done for 1 h. Bands were detected using ECL 
chemiluminescence methods (Pierce Thermo Scientific).  
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2.2.5 RNA Extraction, RT-PCR, qPCR 
Total RNA isolation was accomplished by using the RNAeasy Mini kit (QIAGEN) followed by 
cDNA conversion (2000 ng/RXN) with Superscript II reverse transcriptase (Invitrogen) and 
random hexamer primers. Subsequently, samples were diluted to a 100uL total volume and RT-
PCR was performed using Taq DNA Polymerase (Roche) with ACTB as the reference gene.  
 
2.2.6 RNA ligase mediated rapid amplification of cDNA ends (RLM-RACE) 
5’ and 3’ RLM-RACE was performed with the GeneRacer™ (Invitrogen) kit. Briefly, 500 ng of 
pooled RNA obtained from FG COLO 357, SW1990, and H1975 cell lines was employed as 
substrate for adaptor ligation. Following adapter ligation, cDNA conversion was performed with 
Superscript II reverse transcriptase and random hexamer primers. Nested, touchdown RT-PCR 
was done using the adapter ligated template cDNA with gene-specific primer (5’-
AGATTCTTTAGGAGACCGCAGT- 3’) and kit primers (5’-GCTGACCTCGTGCTCCTGTGACT-
3’ and 5’-CCTGTGACTGTACCTGACTTCCTCATCTTT-3’). Likewise, 3’-RACE was done using 
gene-specific primers (5’- ACTGCGGTCTCCTAAAGAATCT-3’ and5’-
ACAGTAGCACTGCAAAAAAGCAAACGTGC-3’) and kit primers (5’-
GCTGTCAACGATACGCTACGTAACG-3’ and 5’-CGCTACGTAACGGCATGACAGTG-5’) for 
corresponding rounds of nested RT-PCR. PCR amplicons were gel purified using the QIAquick 
gel extraction kit (Qiagen) followed by cloning into PCR2.1 using the TOPO TA cloning Kit 
(Invitrogen). Subsequently, multiple clones were submitted for to the UNMC High-Throughput 
DNA Sequencing and Genotyping Core Facility for sequencing of clones. Sequence annotation 
was done using the Genome Reference Consortium assembly of the human genome (GRCh38) 
at ensembl.org. Sequencing results have been submitted to NCBI GenBank. 
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2.2.7 Growth Kinetics 
Cell proliferation analysis of the BMP-2 gene panel (VC, rh, BSV, RC, lnc, and KD) was 
performed over a 72-hour period. Viz., HupT3 cells were plated in triplicate (2.5 x 105), 
maintained in DMEM (supplemented with 10% FBS and 100 U/mL penicillin-streptomycin), and 
counted at the time point indicated. 
 
2.2.8 Metabolic Activity 
Cellular metabolic activity of the BMP-2 gene panel (VC, rh, BSV, RC, lnc, and KD) was 
assessed by use of the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay. HupT3 cells were seeded in a 96-well format at 2.0 x 104 cells/well 24 h prior to MTT 
assay. Subsequently, freshly prepared cell permeable MTT reagent was added at a final 
concentration of 0.5 mg/mL and then incubated in the dark at 37° in a 5% CO2 chamber. 
Following 4 h, media was removed and replaced with 100 µL of DMSO and absorbance was 
measured at λ = 540 nm. 
 
2.2.9 GF-AFC Cell Viability Assay 
Cell viability analysis of the BMP-2 gene panel (VC, rh, BSV, RC, lnc, and KD) was determined 
by use of the cell permeable live cell protease substrate GF-AFC (glycyl-phenylalanyl-
aminofluorocoumarin). GF-AFC (Promega), is taken up by live cells wherein the cleavage of this 
fluorogenic compound results in fluorescent signal proportional to the number of living cells. The 
HupT3 gene cassette panel cells were seeded in a 96-well format at 2.0 x 104 cells/well 24 h 
prior to GF-AFC viability assay was performed. As an assay control, HupT3 cells were treated 
with Staurosporine (1 µM) for 3 h prior to fluorometric measure of the assay (490 nmex / 510-570 
nmem). 
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2.2.10 Caspase 3/7 Activity Assay 
The caspase 3/7 activity plays an important role in mediating apoptosis. To measure the relative 
caspase 3/7 activity among the BMP-2 gene panel members (VC, rh, BSV, RC, lnc, and KD), a 
luminogenic caspase 3/7 substrate (Promega) was employed. The HupT3 gene panel members 
were seeded in 96-well format 24 h prior to caspase 3/7 activity measurement was performed. 
As an assay control, HupT3 cells were treated with Staurosporine (1 µM) for 3 h prior to 
luminometric measure of caspase 3/7 activity. 
 
2.2.11 Transwell Migration Assay and Transwell Invasion Assay 
The directional migration and invasion in response to a chemo-attractant gradient of the BMP-2 
gene panel was assessed by use of the in vitro transwell migration and invasion assay. Briefly, 
5.0 x 105 cells were seeded into the upper chamber of the transwell insert under serum free 
conditions. After allowing 8 h for cells to attach, the media of the lower chamber was replaced 
with serum containing DMEM and subsequently maintained in humidified incubator at 37° in 5% 
CO2 for an additional 24 h. After 24 h the cells were fixed, stained, and counted under bright 
field microscopy at10x magnification. A representative number of fields were imaged and 
counted (ImageJ) to assess the number of cells able to pass through the membrane’s 0.8 µM 
pores. In rh-BMP2 treated HupT3 cells, the cells were seeded into rhBMP2 (50 ng/mL) 
containing media and serum replaced in the lower chamber was also rhBMP2 (50 ng/mL) 
bearing.  
 
2.2.12 Wound Healing Assay 
As a second measure of migration, 5 x 105 of the BMP-2 gene panel cells were seeded in 12-
well plates. Following 24 h, a wound/scratch was made horizontally and vertically across the 
diameter of the wells. Subsequently, images were taken using phase contrast microscopy at10x 
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magnification. The rate of change for the closure of the wound/scratch was calculated for each 
of the panel members and plotted accordingly. 
 
2.2.13 List of Primers 
The following primers were employed for the various expression vector constructs (Integrated 
DNA Technologies or *eurofins): 
 
Exon 1_BMP2_F: CATGTGGACGCTCTTTCAATGGACGT 
Exon 3_BMP2_R:  TCGGAAAACCTGAAGCTCTGCTGAGGT 
CMV10-BSV F:  CGGTAGATCTGCAAGATGCTTTAGGAAA 
CMV10-BSV R: TTTGGATCCCTAGCGACACCCAC 
*5prmBMP2crspPlus:  PHOS-CACCGGTTGAATAACGGGCCCAGCG 
*5prmBMP2crspMinus:  PHOS-AAACCGCTGGGCCCGTTATTCAACc 
*3prmBMP2crspPlus:  PHOS-CACCGGAACACTTACCAGAGTGTCA 
*3prmBMP2crspMinus:  PHOS-AAACTGACACTCTGGTAAGTGTTCc 
ACTB_F: CTGGCATCGTGATGGACTCCGGTGA 
ACTB_R: AAGGTGGACAGCGAGGCCAGGAT 
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2.3 Results 
 
2.3.1 Meta-Analysis of Pancreatic Expression Profiles Reveals Bone Morphogenetic 
Protein 2 to be Upregulated in Subset of Pancreatic Cancer Samples 
Using Meta-Cancer Outlier Profile Analysis (MCOPA), a bioinformatics tool for the 
enrichment of genes preferentially increased in data subsets (www.oncomine.org), we have 
examined the microarray expression profile of 11 datasets consisting of 358 pancreatic cancer 
samples (Table 2.1.1). Through this analysis, we discovered BMP-2 to be elevated in a subset 
of pancreatic cancer derived microarray experiments (Figure 2.1.1). Subsequently we 
performed validation of the bioinformatics predicted gene candidate by RT-PCR through the use 
of primer probes that spanned the various BMP-2 introns (i.e. Exon 1:Exon 2, Exon 2:Exon 3 or 
Exon 1:Exon 3). Although to date, only a singular transcript representing the BMP-2 gene has 
been reported (ENST00000378827) consisting of 3 exons (Figure 2.2.1 C) we observed an 
unexpected pattern of amplification suggesting an alternative splicing of the BMP-2 transcript. 
As can be seen in a panel of pancreatic cancer cell lines and a cohort of patient derived 
pancreatic samples, there is an amplification of both a 535 bp and 182 bp amplicon (Figure 
2.4.1 A and Figure 2.4.1 B). Upon subsequent investigation, a sequence corresponding to an 
unreported Exon 1:Exon 3 transcriptional variant was detected and verified through DNA 
sequencing (Figure 2.2.1 A). 
To comprehensively annotate the sequence, we next performed 5’ and 3’ RNA ligase 
mediated rapid amplification of cDNA ends (RLM-RACE) followed by cDNA sequencing of the 
product to elucidate the complete transcriptional content. Sequencing of the products following 
RLM-RACE further revealed that in addition to alternative splicing, the transcript also possessed 
truncated 5’ and 3’ untranslated regions (See Table 2.2.1 and Table 2.2.2) for complete 
sequence). The functional implication of the BMP-2 splice variant (BSV) is apparent when 
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compared with that of the BMP-2 full-length (BFL) translational sequence (Figure 2.2.1 B and 
Figure 2.2.1 D). As previously stated, canonical BMP-2 maturation depends upon entry into the 
secretory pathway for the proteolytic cleavage of the pro-protein region and subsequent 
secretion. However, owing to exclusion of the signal peptide bearing exon (E2), the customary 
molecular fate of this molecule is significantly altered resulting in a novel subcellular localization. 
How then do the changes to nucleotide and peptide sequences affect the molecular 
properties of this protein? Using the Center for Biological Sequence Analysis SignalP 4.1 and 
SecretomeP 2.0 prediction servers, we screened for the presence of either a classical or non-
classical signal peptide bearing sequence in the BSV. As anticipated, our analysis of the splice 
variant failed to yield sequence indicative of an alternative secretory signal motif (canonical or 
non-canonical). Thus, the putative BSV ORF likely corresponds to an intracellularly retained 
isoform.  
While our own in silico analysis and the identification of intracellular BMP-2 variants 
reported in the literature would suggest the presence of the intracellular isoform, we sought to 
confirm its endogenous expression by performing a more in depth screening of a cohort of 
representative pancreatic cancer cell lines for the BSV transcript and protein expression. A 
screening of HPDE, Capan-1, CD18\HPAF, FG/Colo357, L3.3, and HupT3 cells was performed 
and both the full-length (BFL) and BSV could be detected at the transcriptional level (Figure 
2.5.1 A). Interestingly, when the same cell lines were examined for BMP-2 protein expression, 
the high molecular weight protein corresponding to the BFL isoform could be detected, but the 
BSV was not readily observed (Figure 2.5.1 B).  
The apparent disparity between transcription and protein abundance suggested to us 
that the novel splice variant may potentially have both coding and non-coding functions. To 
further explore the likelihood that this transcript may behave as a long non-coding RNA variant, 
we performed an in silico analysis of the of the BSV sequence. Using the ORF Finder housed at 
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the National Center for Biotechnology Information (NCBI), we first examined the corresponding 
sequence of the alternatively spliced variant for ORFs greater than 75 a.a. in length. As shown, 
there were 6 ORFs that met this criteria (Table 2.3.1). Furthermore, as the probability a 
particular ORF will be utilized depends on the consensus sequence preceding the translational 
start codon, we assessed the strength of the Kozak sequence for each putative ORF (Kozak 
1986). As predicted by the Center for Biological Sequence Analysis prediction server (CBS), two 
of the 6 predicted ORFs possessed a Kozak sequence with a probability score above the 0.5 
cutoff. The largest ORF corresponded to the sequence we have associated with the BSV. The 
second ORF was a downstream ORF that was in frame with both the BFL and BSV. Most 
importantly, as the a.a. sequence is conserved among the ORFs, our subsequent screening 
with the C-terminal BMP-2 antibody would be able detect their protein expression in the cell line 
screening. While it may be possible that other short open reading frames (sORFs < 75 a.a.) 
could be generated, this is an unavoidable pitfall in expression of a sequence of unknown 
coding potential. Consequently, the absence of any detectable translational product or novel 
ORFs are suggestive of a long non-coding RNA variant. Thus, we subsequently investigated the 
influence the coding and non-coding elements of this gene cassette may have on the BMP-2 
signal transduction pathway and on the functional implications in pancreatic cancer cells. 
In addition to the RT-PCR screening on the PC cell line panel, we performed high-
throughput RNA-sequencing and subsequent differential expression analysis of HPDE and 
HupT3. As anticipated, this analysis revealed many differences between HPDE (normal-
immortalized) and the HupT3 PC cell line. However, there were no statistically significant 
differences observed in the various BMP-2 pathway effectors or inhibitors (Figure 2.5.1 C). 
Thus, while the general expression among the BMP pathway genes may be similar, differences 
in expression and translational products may vary. 
 
27 
 
2.3.2 Influence of BMP-2 SV Expression on rh-BMP2 Dependent Smad 1/5/8 
Phosphorylation 
 To characterize how expression of the intracellular coding isoform of bone 
morphogenetic protein 2 may impact the intensity and duration of the BMP-2 signaling pathway, 
we have stably transfected HEK293 cells with either the p3xFLAG-CMV10 vector alone (VC) or 
the p3xFLAG-CM10 bone morphogenetic protein 2 splice variant (BSV). Subsequently these 
cells were treated with rh-BMP2 and assayed for the induction of Smad 1/5/8 phosphorylation 
by immunoblotting. While there are a number of influences on BMP-2 signal transduction, we 
have additionally assessed the extent to which receptor activation, endocytosis, and autophagy 
may alter Smad 1/5/8 phosphorylation. 
 Following stable transfection, the lysates of the VC and BSV transfected HEK293 cells 
were collected and the presence of the FLAG-tagged BSV was confirmed by immunoblotting 
(Figure 2.6.1 A). As anticipated, the presence of the FLAG-tagged BSV (≈ 34 KDa) was only 
detected in the BSV and not VC samples. Furthermore, when VC and BSV cells were treated 
with rh-BMP2, an increase in Smad 1/5/8 phosphorylation could be seen in BSV transfected 
cells relative to the VC (Figure 2.6.1 B). Thus, an increase in the intracellular isoform appears 
to promote the extracellular BMP-2 mediated signal transduction. 
To understand whether the increase in Smad 1/5/8 phosphorylation was being facilitated 
by the BMP-2 receptor (BMPR1a or BMPR1b), cells were pretreated with either DMSO or the 
BMPR1 inhibitor dorsomorphin. Subsequently, a 1 h incubation with rh-BMP2 was performed 
and an assay of Smad 1/5/8 phosphorylation was done by immunoblotting. Relative to the 
DMSO treated samples, there was complete attenuation upon dorsomorphin inhibition (Figure 
2.6.2 A and 2.6.2 B). Thus, the increase in rh-BMP2 responsiveness is likely dependent on 
BMPR1a activity. 
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 In addition to ligand and receptor interactions, it has been shown that endocytosis plays 
an integral part in regulating signal transduction (Sorkin, von Zastrow 2009). Thus, to 
understand how receptor mediated endocytosis may influence rh-BMP2 activation we have 
measured VC and BSV responsiveness with and without hypertonic sucrose inhibition of 
endocytosis. As shown, the Smad 1/5/8 phosphorylation was attenuated upon pre-treatment of 
VC and BSV with rh-BMP2 in hypertonic sucrose (Figure 2.6.3). Therefore, the increase in rh-
BMP2 responsiveness is also dependent upon receptor mediated endocytosis. 
Finally, we have determined BSV to be preferentially degraded by the autophagy 
lysosome pathway (ALP). As shown, while treatment with the proteasome inhibitor MG-132 
hand negligible impact on the abundance of FLAG-tagged BSV, the treatment with the ALP 
inhibitor vinblastine led to an increase in the abundance of FLAG-tagged BSV (Figure 2.6.4 A). 
Furthermore, to assess the effect that altered autophagic flux may have on signal transduction 
in the context of BSV expression, HEK293 cells were treated with vinblastine and the induction 
of Smad 1/5/8 phosphorylation was subsequently assessed following treatment with rh-BMP2. 
As shown, decreased Smad 1/5/8 phosphorylation could be observed upon inhibition of 
autophagy with an increase in the autophagy marker LC3-II (Figure 2.6.4 B). Furthermore, 
upon induction of autophagy using rapamycin, a corresponding increase in Smad 1/5/8 
phosphorylation could be observed (Figure 2.6.4 C). Thus, the intracellular variant appears to 
influence rh-BMP2 dependent signal transduction in a receptor/endocytosis dependent manner 
that is proportionally influenced by autophagic flux. 
 
2.3.3 Characterization of the Non-coding lnc BMP-2 Expression Impact on rh-BMP2 
Dependent Smad 1/5/8 Phosphorylation.  
 While, morphogenetic protein signaling is largely a consequence of the extracellular 
ligand, we wished to understand how the potentially non-coding transcript of the BMP-2 gene 
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cassette may influence the intensity of rh-BMP2 mediated Smad 1/5/8 phosphorylation (Figure 
2.3.1). Furthermore, our previous observations regarding this pathway suggest that BMP-2 
mediated signaling is reliant upon receptor activity and further influenced by endocytosis and 
autophagy. Thus, we performed immunobloting of total-Smad 1/5/8, phospho-Smad 1/5/8, 
BMPR1a, or LC3-II in vector (V) or lnc (l) transduced HupT3 cells following rh-BMP (100 ng/mL) 
stimulation.  
As shown, under basal/unstimulated conditions, there is a relative increase in Smad 
1/5/8 phosphorylation (Figure 2.7.1 A). Furthermore, upon subsequent treatment with rh-BMP2, 
we also observed relative increases in phospho-Smad 1/5/8 intensities (Figure 2.7.1 B). These 
findings suggest a lnc induced increase in BMP-2 sensitivity. 
In contrast, a total loss of Smad 1/5/8 phosphorylation was seen upon BMPR1a 
inhibition with dorsomorphin Figure 2.7.1 C). Furthermore, inhibition of endocytosis by 
hypertonic sucrose treatment also led to an abrogation of phospho-Smad 1/5/8 intensity (Figure 
2.7.1 D). Consequently, the lnc influence on BMP-2 signaling appears to be both receptor and 
endocytosis dependent. 
Our previous observations would suggest a degree of crosstalk between the BMP-2 
pathway and autophagy. Furthermore, we observed an increase in LC-3 II abundance upon 
BMP-2 treatment with a higher accumulation in the lnc transduced samples as compared with 
VC. To determine the influence of autophagy on BMP-2 signaling, we induced autophagy by 
either 24 h serum starvation or 6 h treatment with rapamycin. Although increased Smad 1/5/8 
phosphorylation in both VC and lnc was detected, the phospho-Smad 1/5/8 intensities were 
greater in lnc transduced cells (Figure 2.7.1 E and Figure 2.7.1 F).  Thus, induction of 
autophagy may participate in modulating bone morphogenetic signaling strength. Furthermore, 
as compared to the VC transduced samples, a greater abundance of LC-3 II could be seen in 
lnc transduced cells suggesting a potential lnc mediated increase in autophagic flux. 
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2.3.4 Expression of non-coding BMP-2 or Total-BMP-2 Knockdown Leads to Altered EMT 
Profile.  
 To validate and extend our understanding of the changes to gene expression observed 
in our qPCR analysis of BMP-2 panel members, we performed immunoblotting of the HupT3 
VC, RC, lnc, and KD samples (Figure 2.8.1). As show, increases in total β-Catenin, phospho-
FAK (Tyr 925) [and to a lesser degree Zeb1] were observed in the RC and lnc expressing 
samples. Strikingly, when examined for relative BMP-2 expression, these samples showed a 
marked decrease in BMP-2 intensity. These observations are consistent with a cell character 
that is shifted towards a mesenchymal profile.  
 Furthermore, when the KD samples were examined for the same markers, a relative 
decrease in the active form of β-Catenin, phospho-FAK (Tyr 925), Zeb1, and BMP-2 were 
observed. In contrast, increases in BCL-2 and vimentin were robustly increased relative to VC, 
RC, and lnc derived samples. The relative decrease in the mesenchymal transcription factors β-
Catenin and Zeb1 would suggest a character that is more epithelial in nature.  
 While EMT markers were measured for expression, we further assessed the extent of 
any potential cytosolic stress as a consequence of non-coding transcript expression. As a 
measure of cytosolic stress, we examined the relative expression of HSP60 and HSP70. As 
shown, the abundance of HSP60 and HSP70 in the VC, RC, lnc, and KD samples remained 
relatively similar.  
 
2.3.5 Cellular Metabolic Activity, Viability, and Caspase 3/7 Activity is Differentially 
Influenced by Expression or Knockdown of BMP-2 Gene Panel. 
 Through the course of generating the HuptT3 BMP-2 panel constituent members (VC, 
rh, BSV, RC, lnc, and KD) we had observed an apparent change in growth rates of cells in 
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culture. Thus, to make a preliminary assessment of the impact expression or knockdown of the 
BMP-2 panel components may have on basic cellular metabolism we have performed a MTT 
assay. The colorimetric assay of HupT3 pancreatic cancer cell line panel members was first 
measured at 24 h after initial seeding of 20 x 103 cells in 96-well format. As reflected in our MTT 
assay, there are varying degrees of effects on cellular metabolism observed depending on the 
contextual expression or knockdown of the BMP-2 panel members (Figure 2.9.1). While there is 
no statistical difference in the VC or KD samples, there are statically significant charges in the 
rh, BSV, RC, and lnc treated and expressing cells (Table 2.9.1).  
 Likewise, the HupT3 cell panel was subsequently assessed at 48 h to determine the of 
effects on cellular metabolism. As shown, there are indeed changes to the cellular metabolism 
profile (Figure 2.10.1). However, statistically significant differences were observed in only the 
BSV samples, which remained depressed relative to the other samples analyzed (Table 2.10.1). 
Given these observations, we further instigated the extent to which these changes may be a 
reflection of the change in cell viability. 
 Consequently, the fluorometric assay of cells were analyzed by GF-AFC assay. 
Similarly, the HupT3 BMP-2 panel was measured following seeding 20 x 103 cells in 96-well 
format. As an assay control, parental cells were treated with staurosporine to chemically reduce 
cell viability. As shown, treatment with staurosporine statistically significantly reduced the MFI 
and confirmed the utility of our assay. Furthermore, our measure of the HupT3 panel yielded a 
range of effects suggesting an impact on cell viability (Figure 2.11.1). In particular, changes in 
viability relative to the VC were observed in rh, BSV, lnc, and KD panel members (Table 
2.11.1).  
 Finally, to further address involvement of the caspase 3/7 pathway in the loss of viability, 
the luminometric measurement of caspase activity was performed (Caspase-Glo ® 3/7). Again, 
as assay control, cells were similarly treated with staurosporine and demonstrated a statistically 
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significant increase in caspase 3/7 activity (Figure 2.12.1). Interestingly, the caspase 3/7 activity 
was determined in the HupT3 panel members and relative to the VC samples, there was a 
relative decrease in caspase 3/7 activity among the rh, BSV, RC, lnc, and KD samples. Thus, 
despite decrease in viability seen in rh, BSV, lnc, and KD panel members, the underlying 
mechanism is independent of caspase 3/7 activity. 
 
2.3.6 Overexpression or Knockdown of the BMP-2 Gene Panel in Pancreatic Cancer Cell 
Line Differentially Affects Migration and Invasive Potential 
 As previously stated, the expression of BMP-2 has been associated with an increase in 
migration and invasiveness (Alarmo, Kallioniemi 2010, Jin, Pi et al. 2012). However, the extent 
to which the expression of the various products of this gene cassette affect these properties 
have yet to be investigated. Thus, to examine how BMP-2 gene panel expression or knockdown 
may influence the functional properties of pancreatic cancer cells, we have employed a 
transwell barrier assay. Interestingly a strikingly broad spectrum of migration was observed 
suggesting a unique and varied role for the constituent members in affecting migration (Figure 
2.13.1). While treatment with rh-BMP2 did not significantly alter the extent to which cells were 
able to pass through the transwell barrier, transduction with either RC or lnc had a statistically 
significant (p < 0.01) fold-increase of 9.5 ± 1.18 and 7.6 ± 0.20 respectively. Furthermore, upon 
knockdown, the extent to which cells passed through the transwell barrier was significantly 
attenuated (Table 2.13.2). Combined, these results strongly implicate the long non-coding BMP-
2 in mediating directional chemotactic migration.  
 As a secondary measure of the migratory potential of these cells, we have also 
performed a wound healing assay wherein a horizontal and longitudinal scratch was produced 
with a pipette tip. Subsequently, closure of the wound, in the absence of any external 
chemotactic induction, was monitored by phase contrast microscopy. Images were captured at 
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0 h, 24 h, and 48 h time-points to assess the extent of wound closure. While all samples 
demonstrated some degree of wound closure, the lnc expression enabled complete resolution 
of the scratch (Figure 2.14.1). 
 Given the increase of lnc mediated migration observed in both transwell migration assay 
and in the wound healing assay we further characterized the invasive properties conferred by 
lnc expression. To do this, an invasion assay was performed, wherein, cells were seeded to 
matrigel coated transwell barrier chambers. Following a 24 h incubation period, the cells were 
assessed for the extent to which they were capable of degrading and invading through the 
transwell barrier. Indeed, the lnc transduced HupT3 cells showed a statistically significant (p < 
0.05) 2.0 ± 0.7-fold increase in invasion (Figure 2.15.1).   
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2.4 Discussion 
As we delve deeper into the molecular influences on cell biology, it has become 
increasingly more apparent that alternative splicing, use of alternative reading frames, and 
expression of non-coding RNA are abundantly employed mechanism by which cells are able to 
both stratify molecular function while coordinating signaling pathways (Shapiro, Cheng et al. 
2011). Here we have employed a bioinformatics meta-analytical approach, wherein BMP-2 
expression was found to be elevated in a subset of pancreatic cancer patient samples. Bone 
morphogenetic protein 2 expression has been shown to be altered in a broad range of 
malignancies including breast, lung, colorectal, and pancreatic cancer (Alarmo, Kallioniemi 
2010, Zhang, Chen et al. 2014). However, our subsequent investigation of the increased BMP-2 
expression in PC suggests that altered expression is a consequence of the transcription of at 
least three variants.  
Previous reports have demonstrated that the full-length transcript of BMP-2 may be 
subject to the use of alternative downstream translational start site (Felin, Mayo et al. 2010, 
Bridgewater, Mayo et al. 2013). The consequence of this shift in reading frame is a truncated 
product that no longer contains a signal peptide and is thus retained intracellularly. The use of 
upstream and downstream ORFs is a nuance of protein translation that is increasingly 
recognized as an adaptive change cells may employ as they transition from a normal biological 
state to one of pathological character (Watkins, Norbury 2002). Indeed, in both normal cell 
biology and in the context of cancer, the selection of translational initiation site is integrated into 
the kinetics of isoform expression (Meric, Hunt 2002). Furthermore, our examination of both cell 
lines and patient derived tissue samples has revealed an alternatively spliced variant whereby 
loss of the upstream translational initiation site and excision of the signal peptide bearing exon 
may lead to an increased utilization of the downstream translational start site that may produce 
a similar isoform.  
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However, upon examination of a panel of cell lines, we were unable to detect a 
significant accumulation of the endogenously produced intracellular BMP-2 isoform. While rapid 
ALP mediated turnover or low expression may contribute to the absence of the intracellular 
BMP-2 in our screen, we nonetheless examined the impact of intracellular BMP-2 expression in 
the context of pancreatic cancer and found expression of the intracellular isoform led to an 
augmented gene transcription profile, decreased viability, and decreased metabolic activity. 
In contrast, the presence of the alternatively spliced transcript was robustly represented 
in multiple cell lines and in numerous patient derived samples. This apparent disparity between 
transcription and translation recommended the transcript may in fact act behave as a long non-
coding variant. Thus, we generated constructs to express the untranslated non-coding RNA 
(lnc) variation of the alternatively spliced variant as well as a construct expressing the reverse 
compliment (RC) of the same corresponding sequence. In this manner, we could determine 
whether expression was dependent upon the primary sequence or whether it was a 
consequence of the chemical properties of the sequence (GC-content, genomic targeting, 
&etc.). When expressed in HupT3 cells, there was a robust increase in markers corresponding 
to increased motility. Furthermore, a robust and statistically significant increase in migration and 
invasiveness was observed in the lnc and RC transduced cells. The similar functional changes 
observed in both lnc (sense) and RC (antisense) transduced cells suggests either the inherent 
chemical properties of the sequence are responsible for the changes seen or the 
complementarity to the genomic may contribute to the biochemical and functional observations 
observed.  
In addition to the similar functional differences observed in lnc or RC transduced HupT3 
cells, we observed a similar decrease in the abundance of BMP-2 by immunoblotting in both 
instances (Figure 2.8.1). Thus, expression of the long non-coding variant or its reverse 
compliment may lead to transcriptional interference or mask certain trans-acting factors 
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necessary for basal expression of BMP-2 (Ard, Tong et al. 2014). Interestingly, when 
CRISPR/Cas9 technology was used for the targeting and knockdown of the entire BMP-2 gene 
cassette, a decrease in RNA abundance and protein expression was observed. However, the 
loss of both the coding and non-coding elements of the BMP-2 gene cassette led to reduced 
expression of EMT markers and decreased migration.  How then do we reconcile the cumulative 
observations regarding the overexpression or knockdown of constituent members of the BMP-2 
gene cassette? 
As previously stated, a hallmark of the BMP superfamily is a characteristic pleiotropy 
observed in the context of cancer wherein the expression of these genes has both oncogenic 
and tumor-suppressive features. Our investigation of the functional properties of the BMP-2 
variants suggest a complex interplay between extracellular ligand, intracellular ligand, and long 
non-coding expression that determines the functional output for this gene. While the 
extracellular ligand and intracellular ligand expression were of a more tumor suppressive 
disposition, the increased expression of the long non-coding BMP-2 variant was more 
oncogenic in nature. Thus, the apparent pleiotropic properties of the entire BMP-2 gene can be 
more finely resolved when considering the individual and cumulative variant contributions.  
While clarification of this point is of particular merit in many cancers, it may be of 
particular relevance in cancers that harbor mutations in the BMP super-family signal 
transduction pathways. The incidence of inactivating receptor mutations is a common 
observance in many epithelial malignancies involving numerous BMP super-family members. 
Furthermore, while many BMP super-family members will employ various receptor-Smad 
proteins to mediate signal transduction, the common mediator Smad 4 is an integral part to this 
cytoplasmic and nuclear shuttling. Indeed, a survey of the Catalogue of Somatic Mutations in 
Cancer (COSMIC; http://cancer.sanger.ac.uk/cancergenome/projects/cosmic) or the 
International Cancer Genome Consortium (ICGC; http://icgc.org/) databases report Smad 4 
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mutations in pancreatic cancer ranging from 15% to 18.7% respectively. The loss of 
extracellular signaling or mediators of this signaling are clearly a common component in the 
molecular genetic profile of pancreatic cancer. Thus, in this context, the continued expression of 
the long non-coding RNA variant may be an important variable in the transition from a benign to 
a malignant state. 
In addition to the long non-coding variant we identified in BMP-2, we have further 
identified possible non-coding products in GDF15 (Growth and Differentiation Factor 15) and in 
TGF-β1 (Transforming Growth Factor Beta 1) through RLM-RACE. Although, we have yet to 
investigate the parallel features in these other BMP superfamily members, our future 
understanding of how long non-coding expression contribute to the oncogenic arm of these 
genes may be a critical hurdle to employing this superfamily of genes for diagnostic or 
therapeutic applications.  
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Figure 2.1.1 
 
 
Figure 2.1.1 General Schematic of the Bioinformatics Workflow Data harvested from 
oncomine.org database consisting of 11 datasets harboring the microarray profiles for 358 
pancreatic cancer samples. Expression data was COPA (Cancer Outlier Profile Analysis) 
transformed and subsequent Meta-Analysis used to identify gene candidates. Heat map 
representative of the genes increased in at least 3 datasets with a corresponding relative COPA 
score indicated. Samples were subsequently screened and validated by RT-PCR before gene 
candidates were selected for further investigation. 
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Figure 2.2.1 
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Figure 2.2.1 Schematic of the BMP-2 Genomic Sequence, Splicing Pattern, and 
Translational Product (A) DNA sequencing chromatogram of the amplicon corresponding to 
the interface of the exon 1 to exon 3 BSV sequence. (B) Primary amino acid sequence of the 
published coding sequencing corresponding to FL BMP-2 with relevant motifs indicated. (C) 
Schematic of the genomic sequence (green) and the corresponding splicing patterns used by 
the FL (Blue) and BSV (Red).  Depiction of both the FL (Blue) and BSV (Red) splicing pattern. 
(D) Primary amino acid sequence of the putative coding sequencing corresponding to BSV with 
relevant motifs indicated. 
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Figure 2.3.1 
 
 
 
Figure 2.3.1 Schematic of the BMP-2 Alternative Splicing and Potential non-coding 
Variant (A) Depiction of both the FL (Blue) and BSV (Red) splicing pattern. (B) Primary 
nucleotide sequence of the putative non-coding sequencing corresponding to BSV employed in 
subsequent cloning and overexpression studies. 
 
 
 
 
 
  
 
A 
B 
 
42 
 
Figure 2.4.1 
 
Figure 2.4.1 RT-PCR Screening of Cell line and Patient Derived Samples Reveal both BFL 
and BSV Expression RT-PCR (30 cycles) screening of cell line panel for BFL and BSV, 
expression. RT-PCR (30 cycles) screening of patient derived samples for BFL and BSV 
expression. ACTB gene expression used as loading control. 
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Figure 2.5.1 
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Figure 2.5.1 BMP-2 Signaling Pathway Expression Profile of Pancreatic Cell Line Cohort 
(A) Semi-quantitative RT-PCR (25 cycles) screening of the cell line panel (HPDE, Capan-1, 
CD18\HPAF, FG/Colo357, L3.3, and HupT3) for BFL, BSV, BMPR1a, BMPR1b, and BMPR2 
expression. ACTB gene expression used as loading control. (B) Immunoblot screening of the 
cell line panel for BMP-2 FL, SV, and BMPR1a expression. Only BMP-2 FL could be observed.  
Beta-Actin serving as loading control. (C) Heat map of the RNA-sequencing analysis the HPDE 
and HupT3 cell lines demonstrating similar and intact BMP-2 pathway expression.  
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Figure 2.6.1 
 
 
Figure 2.6.1 BSV Expression Leads to Increased BMP-2 Dependent Smad 1/5/8 
Phosphorylation (A) Screening for expression of the FLAG-tagged BSV in VC and BSV 
transfected HEK293 cells. (B) HEK293 cells transfected with either VC or BSV were serum 
starved for 1 h, treated with rh-BMP-2 for 1 h, and then assessed by immunoblot for Smad 1/5/8 
phosphorylation. BSV transfected cells show an increased response to rh-BMP2 stimulation as 
compared to cells transfected with the VC. Beta-Actin was also probed and run on a separate 
gel. 
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Figure 2.6.2 
 
 
Figure 2.6.2 BSV Mediated Increase in Smad 1/5/8 Phosphorylation is Receptor 
Dependent (A) Relative Smad 1/5/8 phosphorylation was measured at 1 h, 4 h, and 8 h time 
points in the presence and absence of the BMPR1 inhibitor dorsomorphin. HEK293 cells were 
serum starved for 1 hour, pre-treated with DMSO or dorsomorphin for 30 min, and then 
incubation with rh-BMP2 for 1 h before being analyzed for Smad 1/5/8 phosphorylation by 
immunoblotting. In cells treated with DMSO alone, there is an increased BMP-2 responsiveness 
in BSV transfected cells relative to VC. (B) Pre-treatment with the BMPR1a inhibitor 
dorsomorphin leads to attenuation of phospho-Smad 1/5/8 induction in both VC and BSV 
transfected cells. Beta-Actin was also probed and run on a separate gel.  
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Figure 2.6.3 
 
Figure 2.6.3 BMP-2 Pathway Activation and Smad 1/5/8 Phosphorylation is Endocytosis 
Dependent rh-BMP2 mediated Smad 1/5/8 phosphorylation is attenuated in both VC and BSV 
transfected HEK293 cells upon inhibition of endocytosis by 30-minute pre-treatment with 
hypertonic sucrose. Beta-Actin was also probed and run on a separate gel. 
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Figure 2.6.4 
 
Figure 2.6.4 Alteration of Autophagy Leads to BSV Accumulation and Differential Smad 
1/5/8 Phosphorylation (A) To assess the proteasome or ALP dependent degradation of the 
BSV, cells were subjected to 8 h treatment with vinblastine, an inhibitor of autophagy, or with 
the proteasomal inhibitor MG-132. Subsequently, the abundance of FLAG-tagged BSV was 
assessed by immunoblotting. Increase in the autophagy marker LC-3 II and BSV were observed 
in the vinblastine treated samples indicating ALP mediated turnover. No change was observed 
in the MG-132 treated samples. (B) The impact on Smad 1/5/8 phosphorylation was assessed 
following inhibition of autophagy with vinblastine. Decreased Smad 1/5/8 phosphorylation could 
be observed upon inhibition of autophagy. (C) In contrast, induction of autophagy using 
Rapamycin for 1 h and 3 h yielded increased Smad 1/5/8 phosphorylation in BSV transfected 
cells upon rh-BMP2 stimulation. Beta-Actin also run and loaded on separate gel. 
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Figure 2.7.1 
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Figure 2.7.1 lnc Expression Leads to Increased BMP-2 Dependent Smad 1/5/8 
Phosphorylation Immunoblot of total-Smad 1/5/8, phospho-Smad 1/5/8, BMPR1a, or LC3-II in 
vector (V) or lnc (l) transduced HupT3 cells following rh-BMP (100 ng/mL) stimulation. (A) Under 
unstimulated conditions, increased basal Smad 1/5/8 phosphorylation is seen in lnc transduced 
cells. (B) Following 1 h rh-BMP2 treatment, increased basal Smad 1/5/8 phosphorylation is 
seen in lnc transduced cells. (C) Loss of Smad 1/5/8 phosphorylation observed upon BMPR1a 
inhibition with dorsomorphin (D) Loss of Smad 1/5/8 phosphorylation upon inhibition of 
endocytosis by 30-minute pre-treatment with hypertonic sucrose. (E) Increased phospho-Smad 
1/5/8 upon induction of autophagy through 24 h serum starvation and 1 h rh-BMP2 treatment (F) 
Smad1/5/8 phosphorylation following induction of autophagy with 6 h treatment with rapamycin. 
Beta-Actin probed and run on separate gel. 
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Figure 2.8.1 
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Figure 2.8.1 Immunoblot Reveals Expression of non-coding BMP-2 or Knockdown Leads 
Altered EMT Profile Immunoblot of BMP-2 Panel members (VC, RC, lnc, and KD) for 
total/active β-Catenin, Total and phospho-FAK (Tyr 925), zeb1, claudin-1, vimentin, BCL-2, 
BMP-2, HSP60, and HSP70. Increased levels of the EMT markers β-Catenin, phospho-FAK 
(Tyr 925) observed relative to VC and lost in KD samples. Beta-Actin re-probed and serving as 
loading control. 
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Figure 2.9.1 
Table 2.9.1 
 Mean Absorbance p-value 
VC 1.6 ± 0.3 _ 
rh 1.43 ± 0.2  p < 0.05 
BSV 1.11 ± 0.1 p < 0.05 
RC 0.6 ± 0.1 p < 0.05 
lnc 0.9 ± 0.02 p < 0.05 
KD 2.4 ± 0.2 p > 0.05 
 
 
Figure 2.9.1 Differential Cellular Metabolic Activity is Observed Under BMP-2 Gene Panel 
Expression or Knock Down HupT3 pancreatic cancer cell metabolic activity was assessed by 
MTT assay following 24 h treatment with vehicle or rh-BMP2. The plot of relative absorbance is 
indicated in Table 10.1 with data displayed as mean ± SE (n=3 with statistical significance 
indicated relative to the VC. 
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Figure 2.10.1 
Table 2.10.1 
 Mean Absorbance p-value 
VC 2.8 ± 0.1 _ 
rh 2.8 ± 0.2 p > 0.05 
BSV 1.1 ± 0.1 p < 0.05 
RC 1.1 ± 0.1 p < 0.05 
lnc 2.5 ± 0.1 P > 0.05 
KD 2.1 ± 0.4 p > 0.05 
 
 
Figure 2.10.1 Differential Cellular Metabolic Activity is Observed Under BMP-2 Gene 
Panel Expression or Knock Down HupT3 pancreatic cancer cell metabolic activity was 
assessed by MTT assay following 48 h treatment with vehicle or rh-BMP2. The plot of relative 
absorbance is indicated in Table 10.2 with data displayed as mean ± SE (n=3 with statistical 
significance indicated relative to the VC. 
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Figure 2.11.1 
Table 2.11.1 
  MFI p-value 
Stauro 54886.1 ± 2335.8 p < 0.01 
VC 71850.7 ± 1321.6 _ 
rh 2965.3 ± 560.4  p < 0.01 
BSV 41255.3 ± 3424.2 p < 0.01 
RC 49817.3 ± 545.5 p > 0.05 
lnc 66913.3 ± 2314.1 p < 0.01 
KD 49369 ± 542.2 p < 0.01 
 
Figure 2.11.1 Cell Viability is Differentially Affected Under BMP-2 Gene Panel Expression 
or Knock Down HupT3 pancreatic cancer cell viability was determined by GF-AFC assay 
following 24 h treatment with vehicle or rh-BMP2. Statistically significant decrease observed 
upon rh-BMP2 treated, BSV, RC, and KD samples. Staurosporine was used as an experiment 
control and shows significant decrease in viability. The plot of the MFI is indicated in Table 11.1 
with data displayed as mean ± SE (n=3) with statistical significance indicated relative to the VC. 
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Figure 2.12.1 
Table 2.12.1 
 Average Luminescence p-value 
Stauro 10374.3 ± 1178.1 
 
p < 0.01 
VC 3672.7 ± 271.7 
 
_ 
rh 1571 ± 102.9 
 
p < 0.01 
BSV 866 ± 85.1 
 
p < 0.01 
RC 1004.3 ± 54.0 
 
p < 0.01 
lnc 1204 ± 93.2 
 
p < 0.01 
KD 939.7 ± 31.7 
 
p < 0.01 
 
Figure 2.12.1 Caspase 3/7 Activity is Diminished Under BMP-2 Gene Panel Expression or 
Knock Down HupT3 pancreatic cancer caspase 3/7 activity was determined by use of 
luminogenic-substrate containing DEVD sequence. Following 24 h treatment with vehicle or rh-
BMP2 alone, the luminescence was measured and plotted. Decreased caspase 3/7 activity was 
observed among all BMP-2 gene cassette constituents relative to VC. The relative intensities 
are indicated in Table 11.1 with data displayed as mean ± SE (n=3) with statistical significance 
indicated relative to the VC. 
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Figure 2.13.1 
 
 
Figure 2.13.1 Bright-Field Images of Differential Migration Upon Expression or Knock 
Down of the BMP-2 Gene Panel Representative bright-field images of the HupT3 pancreatic 
cancer cell migration following 24 h transwell migration assay. Images were captured under 10x 
magnification with individual nuclei being counted. Increased migration can be seen in the RC 
and lnc transduced cell lines with loss in cell migration observed upon KD. 
 
 
 
 
 
 
‡Less than 1 cell seen per 10x field in KD sample 
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Figure 2.13.2 
Table 2.13.2 
 Mean Fold-Change p-value 
VC 1.0 ± 0.2 
 
_ 
rh 1.73 ± 0.88 
 
p < 0.01 
BSV 2.52 ± 0.27 
 
p < 0.01 
RC 9.5 ± 1.18 
 
p < 0.01 
lnc 7.6 ± 0.20 
7.6 ± 0.20 
 
p < 0.01 
KD ‡ p < 0.01 
 
Figure 2.13.2 Migration is Differentially Impacted by the Expression or Knock Down of the 
BMP-2 Gene Panel HupT3 pancreatic cancer migration was determined by use of transwell 
migration assay. A total of 5.0 x 105 HupT3 cells were seeded in transwell barrier chambers. 
The experiment was run over a 24 h period and cells were subsequently stained and nuclei per 
field counted. Significant increases observed in RC and lnc transduced samples and lost upon 
KD. The relative fold-changes are indicated for the biological replicates in Table 13.2 with data 
displayed as mean ± SE (n=3) with statistical significance indicated relative to the VC. 
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‡Less than an average of 1 cell seen per 10x field in KD sample 
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Figure 2.14.1 
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Figure 2.14.1 Wound Healing Assay Reveals Differential Migration Upon Expression or 
Knock Down of the BMP-2 Gene Panel Phase-contrast images of HupT3 pancreatic cancer 
cell migration at 0 h, 24 h, and 48 h time-points. Images were captured under 10x magnification 
with representative images shown. Partial wound healing observed in VC, BSV, RC, and KD 
samples with complete wound closure observed in lnc expressing cells. 
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Figure 2.15.1 
 
Figure 2.15.1 Invasion is Differentially Impacted by the Expression the lnc BMP-2 Variant 
HupT3 pancreatic cancer cell invasion was determined by use of matrigel coated transwell 
chambers. A total of 5.0 x 105 HupT3 cells were seeded in transwell barrier chambers. The 
experiment was run over a 24 h period and cells were subsequently stained and counted. (A) 
Representative images using bright-field microscopy taken under 10 x magnification of VC and 
lnc invading cells. (B) Relative cells per 10 x field are indicated with data displayed as mean ± 
SE (n=3) with statistical significance indicated relative to the VC. 
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Table 2.1.1 Pancreatic Cancer META Analysis 
Obs study Rank COPA Gene perc COUNT 
1 Segar 16 33.648 APOC3 95 5 
2 Bedea 75 18.992 APOC3 95 5 
3 Pei 65 16.772 APOC3 90 5 
4 Logsd 38 6.687 APOC3 95 5 
5 Logsd 31 6.039 APOC3 90 5 
6 Ishik 49 5.160 APOC3 90 5 
7 Pei 8 59.302 XIST 95 4 
8 Pei 3 57.938 XIST 90 4 
9 Pei 1 53.651 XIST 75 4 
10 Grutz 52 46.350 XIST 75 4 
11 Bedea 4 6.494 XIST 75 4 
12 Ishik 16 2.662 XIST 75 4 
13 Segar 7 44.164 SLC26A3 95 4 
14 Bedea 11 43.376 SLC26A3 95 4 
15 Pei 33 39.796 SLC26A3 95 4 
16 Bedea 4 23.371 SLC26A3 90 4 
17 Pei 88 15.009 SLC26A3 90 4 
18 Ishik 68 6.634 SLC26A3 95 4 
19 Pei 35 39.549 LOC100129 95 4 
20 Pei 21 27.833 LOC100129 90 4 
21 Segar 94 22.392 LOC100129 95 4 
22 Pei 48 4.848 LOC100129 75 4 
23 Jimen 43 3.497 LOC100129 75 4 
24 Bedea 82 3.206 LOC100129 75 4 
25 Bedea 24 32.516 FABP1 95 4 
26 Pei 58 32.175 FABP1 95 4 
27 Segar 62 24.942 FABP1 95 4 
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Obs study Rank COPA Gene perc COUNT 
28 Pei 29 22.373 FABP1 90 4 
29 Segar 9 21.549 FABP1 90 4 
30 Bedea 9 20.524 FABP1 90 4 
31 Iacob 10 10.781 FABP1 95 4 
32 Bedea 7 5.637 FABP1 75 4 
33 Pei 72 29.624 LOC100128 95 4 
34 Buchh 52 13.549 LOC100128 95 4 
35 Jimen 93 9.796 LOC100128 95 4 
36 Jimen 95 9.724 LOC100128 95 4 
37 Jimen 27 8.208 LOC100128 90 4 
38 Jimen 46 7.730 LOC100128 90 4 
39 Jimen 3 5.392 LOC100128 75 4 
40 Ishik 28 2.484 LOC100128 75 4 
41 Segar 69 24.038 CRP 95 4 
42 Jimen 8 16.428 CRP 95 4 
43 Segar 27 16.172 CRP 90 4 
44 Segar 1 12.219 CRP 75 4 
45 Bedea 23 4.347 CRP 75 4 
46 Pei 90 4.154 CRP 75 4 
47 Grutz 37 18.568 GP2 75 4 
48 Pei 55 17.549 GP2 90 4 
49 Pei 17 7.307 GP2 75 4 
50 Logsd 24 3.930 GP2 75 4 
51 Bedea 46 3.626 GP2 75 4 
52 Buchh 9 9.431 CFTR 90 4 
53 Pei 28 5.936 CFTR 75 4 
54 Jimen 16 4.134 CFTR 75 4 
55 Ishik 15 2.686 CFTR 75 4 
64 
 
Obs study Rank COPA Gene perc COUNT 
56 Segar 1 72.684 NAV3 95 3 
57 Grutz 94 61.196 NAV3 95 3 
58 Grutz 58 53.513 NAV3 90 3 
59 Segar 31 15.761 NAV3 90 3 
60 Jimen 84 10.069 NAV3 95 3 
61 Jimen 36 7.938 NAV3 90 3 
62 Bedea 1 71.927 ALDOB 95 3 
63 Segar 60 25.234 ALDOB 95 3 
64 Buchh 77 2.234 ALDOB 75 3 
65 Pei 3 69.439 GUCA1C 95 3 
66 Pei 2 63.316 GUCA1C 90 3 
67 Pei 8 11.295 GUCA1C 75 3 
68 Bedea 68 8.664 GUCA1C 90 3 
69 Bedea 1 6.837 GUCA1C 75 3 
70 Jimen 72 3.221 GUCA1C 75 3 
71 Bedea 2 69.422 TMPRSS15 95 3 
72 Pei 9 58.536 TMPRSS15 95 3 
73 Segar 27 31.380 TMPRSS15 95 3 
74 Pei 15 31.050 TMPRSS15 90 3 
75 Bedea 5 22.747 TMPRSS15 90 3 
76 Grutz 69 68.187 ABCB11 95 3 
77 Jimen 52 3.410 ABCB11 75 3 
78 Maser 71 1.999 ABCB11 75 3 
79 Pei 6 66.900 APOA1 95 3 
80 Ishik 1 11.765 APOA1 95 3 
81 Ishik 1 11.203 APOA1 90 3 
82 Iacob 96 7.329 APOA1 95 3 
83 Bedea 3 64.226 MTTP 95 3 
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Obs study Rank COPA Gene perc COUNT 
84 Pei 49 33.577 MTTP 95 3 
85 Bedea 45 9.975 MTTP 90 3 
86 Iacob 73 7.675 MTTP 95 3 
87 Pei 7 62.974 DEFA5 95 3 
88 Bedea 9 48.337 DEFA5 95 3 
89 Segar 13 34.761 DEFA5 95 3 
90 Pei 75 15.622 DEFA5 90 3 
91 Bedea 62 9.048 DEFA5 90 3 
92 Bedea 6 58.674 FLJ22763 95 3 
93 Pei 38 37.289 FLJ22763 95 3 
94 Bedea 88 8.235 FLJ22763 90 3 
95 Ishik 78 2.199 FLJ22763 75 3 
96 Pei 14 52.703 PM20D1 95 3 
97 Pei 9 36.283 PM20D1 90 3 
98 Iacob 7 11.515 PM20D1 95 3 
99 Iacob 2 10.951 PM20D1 90 3 
100 Pei 12 8.339 PM20D1 75 3 
101 Bedea 45 3.671 PM20D1 75 3 
102 Iacob 11 2.937 PM20D1 75 3 
103 Pei 15 52.429 DAZ1 95 3 
104 Pei 11 35.391 DAZ1 90 3 
105 Bedea 22 34.213 DAZ1 95 3 
106 Iacob 18 9.513 DAZ1 95 3 
107 Pei 10 55.685 DAZ2 95 3 
108 Segar 23 32.131 DAZ2 95 3 
109 Pei 16 29.170 DAZ2 90 3 
110 Bedea 45 24.241 DAZ2 95 3 
111 Segar 40 14.917 DAZ2 90 3 
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Obs study Rank COPA Gene perc COUNT 
112 Pei 21 45.910 ALB 95 3 
113 Pei 10 36.068 ALB 90 3 
114 Pei 6 12.453 ALB 75 3 
115 Iacob 6 11.937 ALB 95 3 
116 Bedea 98 7.845 ALB 90 3 
117 Iacob 34 5.666 ALB 90 3 
118 Bedea 32 3.996 ALB 75 3 
119 Bedea 10 43.617 KRT20 95 3 
120 Bedea 1 37.643 KRT20 90 3 
121 Segar 30 30.940 KRT20 95 3 
122 Segar 6 23.576 KRT20 90 3 
123 Pei 64 4.564 KRT20 75 3 
124 Bedea 20 4.408 KRT20 75 3 
125 Pei 26 43.371 DEFA6 95 3 
126 Bedea 16 38.864 DEFA6 95 3 
127 Jimen 14 14.185 DEFA6 95 3 
128 Bedea 12 42.984 APOB 95 3 
129 Pei 39 35.921 APOB 95 3 
130 Segar 28 31.330 APOB 95 3 
131 Pei 18 28.569 APOB 90 3 
132 Bedea 85 8.320 APOB 90 3 
133 Segar 8 40.879 CXCL5 95 3 
134 Pei 81 4.259 CXCL5 75 3 
135 Logsd 88 2.512 CXCL5 75 3 
136 Pei 34 39.780 LOC100131 95 3 
137 Pei 23 26.352 LOC100131 90 3 
138 Segar 89 12.630 LOC100131 90 3 
139 Iacob 86 7.445 LOC100131 95 3 
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Obs study Rank COPA Gene perc COUNT 
140 Iacob 45 5.509 LOC100131 90 3 
141 Segar 14 34.642 MSMB 95 3 
142 Bedea 33 27.855 MSMB 95 3 
143 Bedea 11 19.260 MSMB 90 3 
144 Segar 24 16.589 MSMB 90 3 
145 Pei 98 14.256 MSMB 90 3 
146 Bedea 31 4.008 MSMB 75 3 
147 Pei 47 33.739 GKN1 95 3 
148 Pei 38 20.192 GKN1 90 3 
149 Bedea 33 10.901 GKN1 90 3 
150 Buchh 69 6.701 GKN1 90 3 
151 Pei 68 30.502 CCL25 95 3 
152 Bedea 55 22.468 CCL25 95 3 
153 Logsd 99 2.414 CCL25 75 3 
154 Pei 73 29.571 C12ORF39 95 3 
155 Pei 56 17.542 C12ORF39 90 3 
156 Pei 41 5.258 C12ORF39 75 3 
157 Iacob 58 5.229 C12ORF39 90 3 
158 Bedea 62 3.394 C12ORF39 75 3 
159 Iacob 17 2.715 C12ORF39 75 3 
160 Pei 79 28.860 SLC1A2 95 3 
161 Pei 28 22.400 SLC1A2 90 3 
162 Pei 25 6.158 SLC1A2 75 3 
163 Bedea 35 3.940 SLC1A2 75 3 
164 Jimen 92 3.086 SLC1A2 75 3 
165 Bedea 34 26.303 CPS1 95 3 
166 Bedea 8 21.949 CPS1 90 3 
167 Maser 54 6.651 CPS1 90 3 
68 
 
Obs study Rank COPA Gene perc COUNT 
168 Iacob 32 2.487 CPS1 75 3 
169 Bedea 47 24.098 CHP2 95 3 
170 Pei 58 17.495 CHP2 90 3 
171 Jimen 52 7.524 CHP2 90 3 
172 Jimen 17 4.130 CHP2 75 3 
173 Segar 99 21.859 HMGA2 95 3 
174 Jimen 52 11.088 HMGA2 95 3 
175 Logsd 95 2.471 HMGA2 75 3 
176 Bedea 92 17.231 EPHA7 95 3 
177 Pei 73 15.693 EPHA7 90 3 
178 Ishik 46 2.337 EPHA7 75 3 
179 Grutz 46 17.038 HLA-DRB4 75 3 
180 Bedea 46 9.945 HLA-DRB4 90 3 
181 Jimen 87 9.942 HLA-DRB4 95 3 
182 Bedea 12 4.919 HLA-DRB4 75 3 
183 Bedea 98 16.367 DSG3 95 3 
184 Bedea 26 11.842 DSG3 90 3 
185 Pei 63 4.579 DSG3 75 3 
186 Ishik 71 2.229 DSG3 75 3 
187 Jimen 16 14.006 LOC100287 95 3 
188 Buchh 69 13.062 LOC100287 95 3 
189 Jimen 5 10.519 LOC100287 90 3 
190 Buchh 39 7.336 LOC100287 90 3 
191 Iacob 57 2.316 LOC100287 75 3 
192 Iacob 84 2.203 LOC100287 75 3 
193 Jimen 18 13.493 FGL1 95 3 
194 Iacob 72 7.768 FGL1 95 3 
195 Iacob 27 5.797 FGL1 90 3 
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Obs study Rank COPA Gene perc COUNT 
196 Segar 92 3.816 FGL1 75 3 
197 Grutz 94 10.549 BMP2 75 3 
198 Segar 79 3.914 BMP2 75 3 
199 Buchh 43 2.454 BMP2 75 3 
200 Logsd 38 5.931 BMP7 90 3 
201 Logsd 4 5.022 BMP7 75 3 
202 Pei 52 4.787 BMP7 75 3 
203 Maser 27 2.272 BMP7 75 3 
204 Bedea 97 7.858 ANK2 90 3 
205 Jimen 94 6.771 ANK2 90 3 
206 Logsd 71 6.044 ANK2 95 3 
207 Logsd 61 5.409 ANK2 90 3 
208 Logsd 19 4.129 ANK2 75 3 
209 Jimen 97 3.071 ANK2 75 3 
210 Buchh 80 12.772 LRRC31 95 3 
211 Bedea 42 10.191 LRRC31 90 3 
212 Pei 15 7.732 LRRC31 75 3 
213 Bedea 72 3.296 LRRC31 75 3 
214 Bedea 91 17.287 MME 95 3 
215 Jimen 11 15.152 MME 95 3 
216 Bedea 35 10.735 MME 90 3 
217 Jimen 39 7.879 MME 90 3 
218 Iacob 87 7.445 MME 95 3 
219 Iacob 100 4.763 MME 90 3 
220 Segar 23 16.683 PENK 90 3 
221 Bedea 82 8.373 PENK 90 3 
222 Buchh 21 2.797 PENK 75 3 
223 Bedea 32 11.020 SERPINB7 90 3 
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Obs study Rank COPA Gene perc COUNT 
224 Ishik 67 6.638 SERPINB7 95 3 
225 Ishik 15 6.204 SERPINB7 90 3 
226 Jimen 42 3.503 SERPINB7 75 3 
227 Iacob 14 6.592 PNLIPRP2 90 3 
228 Logsd 77 2.562 PNLIPRP2 75 3 
229 Iacob 42 2.398 PNLIPRP2 75 3 
230 Buchh 56 2.377 PNLIPRP2 75 3 
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Table 2.2.1 BMP-2 FL Nucleotide Sequence: Published Sequence obtained from Ensembl 
Database including the 5’ UTR, Coding Sequence, and 3’UTR 
GCCGCGAGCGCCGCGCCACGGCGCCGCCGCCGCCGTCGCCGCCGCCGGAGTCCTCGC
CCCGCCGCGCTGCGCCCGGCTCGCGCTGCGCTAGTCGCTCCGCTTCCCACACCCCGCCG
GGGACTGGCAGCCGCCGCCGCACATCTGCCGCCACAGCCTCCGCCGGCTACCCGAACGT
TCTCGGGGCCAGCGCCGAGTGGATCACCGGGGACCGCGAGGCACCCGCGCGCCGCAGA
CCCCGCGCGGGCTGGAGCACCCGGCAGAGCGCGCCACAGCGCCGTGGCCTCTGCTGCC
CGGGCTGCGCCAGAGCCGCGGACGGGCGCGCAGAGCGCCGGGGACTCCGGAGCCGAT
CCCTAGCGCCGCGATGCGGAGCACCTACTGCAGGAGATCGGGGGCCTGGGACGCGCTG
GCCGAGGTGTGATCGGACCCCAGGCTAGCCACAAAGGGCACTTGGCCCCAGGGCTAGGA
GAGCGAGGGGAGAGCACAGCCACCCGCCTCGGCGGCCCGGGACTCGGCTCGACTCGCC
GGAGAATGCGCCCGAGGACGACGGGGCGCCAGAGCCGCGGTGCTTTCAACTGGCGAGC
GCGAATGGGGGTGCACTGGAGTAAGGCAGAGTGATGCGGGGGGGCAACTCGCCTGGCA
CCGAGATCGCCGCCGTGCCCTTCCCTGGACCCGGCGTCGCCCAGGATGGCTGCCCCGAG
CCATGGGCCGCGGCGGAGCTAGCGCGGAGCGCCCGACCCTCGACCCCCGAGTCCCGGA
GCCGGCCCCGCGCGGGGCCACGCGTCCCTCGGGCGCTGGTTCCTAAGGAGGACGACAG
CACCAGCTTCTCCTTTCTCCCTTCCCTTCCCTGCCCCGCACTCCTCCCCCTGCTCGCTGTT
GTTGTGTGTCAGCACTTGGCTGGGGACTTCTTGAACTTGCAGGGAGAATAACTTGCGCAC
CCCACTTTGCGCCGGTGCCTTTGCCCCAGCGGAGCCTGCTTCGCCATCTCCGAGCCCCAC
CGCCCCTCCACTCCTCGGCCTTGCCCGACACTGAGACGCTGTTCCCAGCGTGAAAAGAGA
GACTGCGCGGCCGGCACCCGGGAGAAGGAGGAGGCAAAGAAAAGGAACGGACATTCGGT
CCTTGCGCCAGGTCCTTTGACCAGAGTTTTTCCATGTGGACGCTCTTTCAATGGACGTGTC
CCCGCGTGCTTCTTAGACGGACTGCGGTCTCCTAAAGGTCGACCATGGTGGCCGGGACC
CGCTGTCTTCTAGCGTTGCTGCTTCCCCAGGTCCTCCTGGGCGGCGCGGCTGGCCTCGTT
CCGGAGCTGGGCCGCAGGAAGTTCGCGGCGGCGTCGTCGGGCCGCCCCTCATCCCAGC
CCTCTGACGAGGTCCTGAGCGAGTTCGAGTTGCGGCTGCTCAGCATGTTCGGCCTGAAAC
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AGAGACCCACCCCCAGCAGGGACGCCGTGGTGCCCCCCTACATGCTAGACCTGTATCGC
AGGCACTCAGGTCAGCCGGGCTCACCCGCCCCAGACCACCGGTTGGAGAGGGCAGCCAG
CCGAGCCAACACTGTGCGCAGCTTCCACCATGAAGAATCTTTGGAAGAACTACCAGAAAC
GAGTGGGAAAACAACCCGGAGATTCTTCTTTAATTTAAGTTCTATCCCCACGGAGGAGTTT
ATCACCTCAGCAGAGCTTCAGGTTTTCCGAGAACAGATGCAAGATGCTTTAGGAAACAATA
GCAGTTTCCATCACCGAATTAATATTTATGAAATCATAAAACCTGCAACAGCCAACTCGAAA
TTCCCCGTGACCAGACTTTTGGACACCAGGTTGGTGAATCAGAATGCAAGCAGGTGGGAA
AGTTTTGATGTCACCCCCGCTGTGATGCGGTGGACTGCACAGGGACACGCCAACCATGGA
TTCGTGGTGGAAGTGGCCCACTTGGAGGAGAAACAAGGTGTCTCCAAGAGACATGTTAGG
ATAAGCAGGTCTTTGCACCAAGATGAACACAGCTGGTCACAGATAAGGCCATTGCTAGTAA
CTTTTGGCCATGATGGAAAAGGGCATCCTCTCCACAAAAGAGAAAAACGTCAAGCCAAACA
CAAACAGCGGAAACGCCTTAAGTCCAGCTGTAAGAGACACCCTTTGTACGTGGACTTCAGT
GACGTGGGGTGGAATGACTGGATTGTGGCTCCCCCGGGGTATCACGCCTTTTACTGCCAC
GGAGAATGCCCTTTTCCTCTGGCTGATCATCTGAACTCCACTAATCATGCCATTGTTCAGAC
GTTGGTCAACTCTGTTAACTCTAAGATTCCTAAGGCATGCTGTGTCCCGACAGAACTCAGT
GCTATCTCGATGCTGTACCTTGACGAGAATGAAAAGGTTGTATTAAAGAACTATCAGGACAT
GGTTGTGGAGGGTTGTGGGTGTCGCTAGTACAGCAAAATTAAATACATAAATATATATATAT
ATATATATTTTAGAAAAAAGAAAAAAACAAACAAACAAAAAAACCCCACCCCAGTTGACACT
TTAATATTTCCCAATGAAGACTTTATTTATGGAATGGAATGGAAAAAAAAACAGCTATTTTGA
AAATATATTTATATCTACGAAAAGAAGTTGGGAAAACAAATATTTTAATCAGAGAATTATTCC
TTAAAGATTTAAAATGTATTTAGTTGTACATTTTATATGGGTTCAACCCCAGCACATGAAGTA
TAATGGTCAGATTTATTTTGTATTTATTTACTATTATAACCACTTTTTAGGAAAAAAATAGCTA
ATTTGTATTTATATGTAATCAAAAGAAGTATCGGGTTTGTACATAATTTTCCAAAAATTGTAG
TTGTTTTCAGTTGTGTGTATTTAAGATGAAAAGTCTACATGGAAGGTTACTCTGGCAAAGTG
CTTAGCACGTTTGCTTTTTTGCAGTGCTACTGTTGAGTTCACAAGTTCAAGTCCAGAAAAAA
AAAGTGGATAATCCACTCTGCTGACTTTCAAGATTATTATATTATTCAATTCTCAGGAATGTT
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GCAGAGTGATTGTCCAATCCATGAGAATTTACATCCTTATTAGGTGGAATATTTGGATAAGA
ACCAGACATTGCTGATCTATTATAGAAACTCTCCTCCTGCCCCTTAATTTACAGAAAGAATA
AAGCAGGATCCATAGAAATAATTAGGAAAACGATGAACCTGCAGGAAAGTGAATGATGGTT
TGTTGTTCTTCTTTCCTAAATTAGTGATCCCTTCAAAGGGGCTGATCTGGCCAAAGTATTCA
ATAAAACGTAAGATTTCTTCATTATTGATATTGTGGTCATATATATTTAAAATTGATATCTCGT
GGCCCTCATCAAGGGTTGGAAATTTATTTGTGTTTTACCTTTACCTCATCTGAGAGCTCTTT
ATTCTCCAAAGAACCCAGTTTTCTAACTTTTTGCCCAACACGCAGCAAAATTATGCACATCG
TGTTTTCTGCCCACCCTCTGTTCTCTGACCTATCAGCTTGCTTTTCTTTCCAAGGTTGTGTG
TTTGAACACATTTCTCCAAATGTTAAACCTATTTCAGATAATAAATATCAAATCTCTGGCATT
TCATTCTATAAAGTC 
 
Table 2.2.2 BMP2 SV Nucleotide Sequence: Sequence for the alternatively spliced BMP-2 
variant (BSV) as determined by 5’RLM-RACE and determined by 3’RLM-RACE 
TTTTCCATGTGGACGCTCTTTCAATGGACGTGTCCCCGCGTGCTTCTTAGACGGACTGCGG
TCTCCTAAAGAATCTTTGGAAGAACTACCAGAAACGAGTGGGAAAACAACCCGGAGATTCT
TCTTTAATTTAAGTTCTATCCCCACGGAGGAGTTTATCACCTCAGCAGAGCTTCAGGTTTTC
CGAGAACAGATGCAAGATGCTTTAGGAAACAATAGCAGTTTCCATCACCGAATTAATATTTA
TGAAATCATAAAACCTGCAACAGCCAACTCGAAATTCCCCGTGACCAGACTTTTGGACACC
AGGTTGGTGAATCAGAATGCAAGCAGGTGGGAAAGTTTTGATGTCACCCCCGCTGTGATG
CGGTGGACTGCACAGGGACACGCCAACCATGGATTCGTGGTGGAAGTGGCCCACTTGGA
GGAGAAACAAGGTGTCTCCAAGAGACATGTTAGGATAAGCAGGTCTTTGCACCAAGATGAA
CACAGCTGGTCACAGATAAGGCCATTGCTAGTAACTTTTGGCCATGATGGAAAAGGGCATC
CTCTCCACAAAAGAGAAAAACGTCAAGCCAAACACAAACAGCGGAAACGCCTTAAGTCCAG
CTGTAAGAGACACCCTTTGTACGTGGACTTCAGTGACGTGGGGTGGAATGACTGGATTGT
GGCTCCCCCGGGGTATCACGCCTTTTACTGCCACGGAGAATGCCCTTTTCCTCTGGCTGA
TCATCTGAACTCCACTAATCATGCCATTGTTCAGACGTTGGTCAACTCTGTTAACTCTAAGA
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TTCCTAAGGCATGCTGTGTCCCGACAGAACTCAGTGCTATCTCGATGCTGTACCTTGACGA
GAATGAAAAGGTTGTATTAAAGAACTATCAGGACATGGTTGTGGAGGGTTGTGGGTGTCGC
TAGTACAGCAAAATTAAATACATAAATATATATATATATATATATTTTAGAAAAAAGAAAAAAA
CAAACAAACAAAAAAACCCCACCCCAGTTGACACTTTAATATTTCCCAATGAAGACTTTATTT
ATGGAATGGAATGGAAAAAAAAACAGCTATTTTGAAAATATATTTATATCTACGAAAAGAAGT
TGGGAAAACAAATATTTTAATCAGAGAATTATTCCTTAAAGATTTAAAATGTATTTAGTTGTA
CATTTTATATGGGTTCAACCCCAGCACATGAAGTATAATGGTCAGATTTATTTTGTATTTATT
TACTATTATAACCACTTTTTAGGAAAAAAATAGCTAATTTGTATTTATATGTAATCAAAAGAAG
TATCGGGTTTGTACATAATTTTCCAAAAATTGTAGTTGTTTTCAGTTGTGTGTATTTAAGATG
AAAAGTCTACATGGAAGGTTACTCTGGCAAAGTGCTTAGCACGTTTGCTTTTTTGCAGTGCT
ACTGTTGAGTTCACAAGTTCAAGTCCAGAAAAAAAAAGTGGATAATCCACTCTGCTGACTTT
CAAGATTATTATATTATTCAATTCTCAGGAATGTTGCAGAGTGATTGTCCAATCCATGAGAAT
TTACATCCTTATTAGGTGGAATATTTGGATAAGAACCAGACATTGCTGATCTATTATAGAAA
CTCTCCTCCTGCCCCTTAATTTACAGAAAGAATAAAGCAGGATCCATAGAAATAATTAGGAA
AACGATGAACCTGCAGGAAAGTGAATGATGGTTTGTTGTTCTTCTTTCCTAAATTAGTGATC
CCTTCAAAGGGGCTGATCTGGCCAAAGTATTCAATAAAACGTAAGATTTCTTCA 
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Table 2.3.1 Open Reading Frame and Translational Start Site Analysis 
 
Predicted CDS Predicted ORF 
Kozak        
Score 
1 
ATGCGGTGGACTGCACAGGGACACGCCA
ACCATGGATTCGTGGTGGAAGTGGCCCA
CTTGGAGGAGAAACAAGGTGTCTCCAAG
AGACATGTTAGGATAAGCAGGTCTTTGCA
CCAAGATGAACACAGCTGGTCACAGATA
AGGCCATTGCTAGTAACTTTTGGCCATGA
TGGAAAAGGGCATCCTCTCCACAAAAGA
GAAAAACGTCAAGCCAAACACAAACAGC
GGAAACGCCTTAAGTCCAGCTGTAAGAG
ACACCCTTTGTACGTGGACTTCAGTGAC
GTGGGGTGGAATGACTGGATTGTGGCTC
CCCCGGGGTATCACGCCTTTTACTGCCA
CGGAGAATGCCCTTTTCCTCTGGCTGAT
CATCTGAACTCCACTAATCATGCCATTGT
TCAGACGTTGGTCAACTCTGTTAACTCTA
AGATTCCTAAGGCATGCTGTGTCCCGAC
AGAACTCAGTGCTATCTCGATGCTGTACC
TTGACGAGAATGAAAAGGTTGTATTAAAG
AACTATCAGGACATGGTTGTGGAGGGTT
GTGGGTGTCGCTAG 
MRWTAQGHANHGFVVEVAHLEEKQG
VSKRHVRISRSLHQDEHSWSQIRPLLV
TFGHDGKGHPLHKREKRQAKHKQRK
RLKSSCKRHPLYVDFSDVGWNDWIVA
PPGYHAFYCHGECPFPLADHLNSTNH
AIVQTLVNSVNSKIPKACCVPTELSAIS
MLYLDENEKVVLKNYQDMVVEGCGC
R 
0.640 
2 
ATGATGGAAAAGGGCATCCTCTCCACAA
AAGAGAAAAACGTCAAGCCAAACACAAA
CAGCGGAAACGCCTTAAGTCCAGCTGTA
AGAGACACCCTTTGTACGTGGACTTCAGT
GACGTGGGGTGGAATGACTGGATTGTGG
CTCCCCCGGGGTATCACGCCTTTTACTG
CCACGGAGAATGCCCTTTTCCTCTGGCT
GATCATCTGA 
MMEKGILSTKEKNVKPNTNSGNALSP
AVRDTLCTWTSVTWGGMTGLWLPRG
ITPFTATENALFLWLII 
0.657 
3 
ATGCCATTGTTCAGACGTTGGTCAACTCT
GTTAACTCTAAGATTCCTAAGGCATGCTG
TGTCCCGACAGAACTCAGTGCTATCTCG
ATGCTGTACCTTGACGAGAATGAAAAGGT
TGTATTAA 
MPLFRRWSTLLTLRFLRHAVSRQNSV
LSRCCTLTRMKRLY 
0.415 
4 
ATGAAGACTTTATTTATGGAATGGAATGG
AAAAAAAAACAGCTATTTTGAAAATATATT
TATATCTACGAAAAGAAGTTGGGAAAACA
AATATTTTAATCAGAGAATTATTCCTTAA 
MKTLFMEWNGKKNSYFENIFISTKRS
WENKYFNQRIIP 
0.226 
5 
ATGGAAAAAAAAACAGCTATTTTGAAAAT
ATATTTATATCTACGAAAAGAAGTTGGGA
AAACAAATATTTTAATCAGAGAATTATTCC
TTAAAGATTTAAAATGTATTTAG 
MYLVVHFIWVQPQHMKYNGQIYFVFIY
YYNHFLGKK 
0.344 
6 
ATGTATTTAGTTGTACATTTTATATGGGTT
CAACCCCAGCACATGAAGTATAATGGTCA
GATTTATTTTGTATTTATTTACTATTATAAC
CACTTTTTAGGAAAAAAATAG 
MEKKTAILKIYLYLRKEVGKTNILIRELF
LKDLKCI 
0.355 
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CHAPTER 3 
 
The Characterization of the Role of Intracellular Amyloid Beta Peptide and its 
Pathophysiological Implications in Alzheimer’s Disease 
 
 
Eric Cruz, Sushil Kumar, Li Yuan, Jyothi Arikkath, and Surinder K. Batra 
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Synopsis 
Alzheimer’s disease (AD) is a neurodegenerative syndrome that is classically depicted 
by the parenchymal accumulation of extracellular amyloid beta positive plaques. However, 
recent findings suggest intracellular amyloid beta (iAβ1-42) expression precedes the formal 
extracellular deposition and plaque formation. Furthermore, the pathologic increase in amyloid 
beta has been implicated in dysregulation of various signaling pathways critical to the 
maintenance of neuronal viability. However, the role of iAβ1-42 and its influence on the 
mitogen:morphogenic signaling axis has not been elucidated. Here, we have performed a 
biochemical characterization of the impact intracellular amyloid beta accumulation has on 
mitogenic and morphogenetic signaling. Our studies reveal an increase in iAβ1-42 expression 
leads to diminished mitogen and increased morphogen signal intensities. Consequently, 
dysregulation of these gatekeepers of neuronal viability may contribute to the observed iAβ1-42 
mediated neurotoxicity observed in AD.  
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3.1 Introduction: 
Alzheimer’s disease (AD) is the most frequently occurring neurodegenerative disorder, 
affecting more than 5 million men and women in the United States [1]. Owing to the 
extraordinary prevalence of this illness and the ever-increasing socioeconomic toll of treating 
and caring for those suffering from AD, investigation of novel strategies to combat AD has 
become imperative. Though the molecular etiological determinants of AD have been extensively 
studied, the precise mechanism in which these changes elicit neurotoxicity remains poorly 
resolved. While a host of changes may contribute to the neuropathological transformation 
associated with AD, the pathognomonic accumulation of amyloid beta resides in the forefront as 
both a diagnostic tool and therapeutic target.  
Patients suffering from AD may exhibit a multitude of changes resulting from the 
advancement of AD including gliosis, vascular defects, inflammation, and cortical and 
hippocampal degeneration (Shepardson, Shankar et al. 2011). While many regions of the brain 
are affected, a high degree of early hippocampal sclerosis and degenerative loss of pyramidal 
neurons is frequently seen (Amador-Ortiz, Dickson 2008). Furthermore, the decline of 
declarative episodic memory characteristically found in patients with AD further implicates 
particular involvement of the hippocampus (Markowitsch, Staniloiu 2012). 
 At the heart of the various pathological transformation associated with AD lies the 
amyloid beta peptide. Amyloid beta peptide formation results from the posttranslational 
processing of amyloid precursor protein (APP), wherein, through the successive endoproteolytic 
activity of β-secretase and γ-secretase, an amyloidogenic peptide fragment is generated. 
Subsequently, the metabolism of APP yields a byproduct of varying size with the 42 amino acid 
isoform being considered the most amyloidogenic (Allen 2007). Furthermore, the assembly of 
the soluble extracellular amyloid beta (eAβ1-42) into oligomers and fibrils is believed to contribute 
to the hallmark parenchymal deposition and pathological activity. However, recent findings 
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regarding the distribution of Aβ1-42 recommends a more varied spectrum of extracellular and 
intracellular localization. 
 While eAβ1-42 has garnered the greatest attention, the intracellular localization of amyloid 
beta (iAβ1-42) is being investigated for it pathophysiological contributions to AD. While the 
precise mechanism of iAβ1-42 localization has yet to be completely elucidated, there is increasing 
evidence supporting a molecular environment that may contribute to an increased intracellular 
pool of amyloid beta. Indeed, it has been recently demonstrated that localization of APP, 
PSEN2, and γ-secretase to the acidified endosomal and lysosomal compartments lead to the 
preferential and intracellular generation of the Aβ1-42 isoform (Sannerud, Esselens et al. 2016). 
While, the molecular properties of the endoproteases may predispose APP to intracellular 
cleavage, the uptake of soluble eAβ1-42 may also serve as a means of introducing and 
increasing pools of intracellular amyloid beta (Lai, McLaurin 2010). Although the precise 
mechanism of intracellular localization is unclear, empirical and clinical observation continue to 
support this potentially new source of amyloid beta mediated pathology.   
In particular, in vivo analysis employing genetically engineered mouse models of AD and 
post-mortem examination of patients with heritable early onset AD (EOAD) have revealed iAβ1-42 
to precede extracellular plaque deposition (Oddo, Caccamo et al. 2003, Gyure, Durham et al. 
2001). Furthermore, the spectrum of intracellular distribution has varied considerably to include 
colocalization within endosomes, multivessicular bodies, lysosomal compartments, 
mitochondria, endoplasmic reticulum, and cytosolic expression [5–8]. While the extracellular 
plaque deposition has not correlated well with neurodegeneration or cognitive decline, iAβ1-42 
has shown better correlation with neuronal loss and cognitive decline using transgenic mouse 
models of AD (Bayer, Wirths 2010, LaFerla, Green et al. 2007). 
 Although there are numerous pathological effects associated with amyloid beta 
accumulation, we have concentrated our efforts on understanding the impact intracellular 
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amyloid beta may have on mitogenic and morphogenetic signaling homeostasis. Decades have 
passed since Rita Levi-Montalcini and Stanley Cohen were awarded the Nobel Prize for their 
discovery of Nerve Growth Factor and their observations regarding this molecule’s ability to 
stimulate nerve growth. Since that time, the discovery of other promoters and antagonists of 
neuronal cell growth and viability have been made and serve as the basis for what has been 
described as the neurotrophic hypothesis (Yuen, Howe et al. 1996). This postulate has been 
used to provide a framework for understanding the cell non-autonomous signaling that 
ultimately governs the preservation of neuronal viability. Indeed, relative concentrations of 
molecular gradients and signaling thresholds maintained by neurotrophic and morphogenetic 
concentrations have been shown to be important mediators of neuronal innervation and pruning 
(Gambaro, Aberdam et al. 2006, Yeo, Gautier 2004). Moreover, neurotrophic protein (i.e. EGF, 
NGF, BDNF, &etc.) and bone morphogenetic protein (i.e. BMP-2, BMP-4, &etc.) dependent 
signaling gradients are critical positive and negative coordinators of neurogenesis, neural 
pathway formation, and programmed cell death (Kristiansen, Ham 2014).  
To circumvent the challenges of investigating an isoform specific byproduct of APP 
processing, with intracellular localization, we have employed an iAβ overexpression model 
system to examine the impact of iAβ1-42 on cellular signaling. Interestingly, in the context of iAβ 
expression, we have demonstrated an inverse and differential influence of mitogenic and 
morphogenetic signaling pathways. Specifically, in the presence of iAβ expression, EGF or 
BDNF dependent ERK1/2 phosphorylation was significantly diminished. In contrast, induction of 
bone morphogenetic protein 2 (BMP-2) dependent receptor Smad 1/5/8 phosphorylation was 
found to be significantly elevated in iAβ expressing cells. These findings suggest a 
pathophysiological role for iAβ1-42 wherein iAβ1-42 accumulation and the analogous neurotoxicity 
observed in clinical AD may be perpetuated through disruption of critical signaling needed for 
maintaining neuronal cell homeostasis. 
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3.2 Materials and Methods: 
 
3.2.1 Cell Culture, Transfections, and Transductions  
Transient transfection was performed using Lipofectamine® 2000 transfection reagent. 
Unless otherwise indicated, cells were analyzed 48 h post-transfection or following stable 
selection. Co-transfection with mRFP-Rab11WT /mRFP-Rab11S25N and MYiAβ1-42was 
accomplished by first transfecting HEK293 cells with either the mRFP-Rab11WT or mRFP-
Rab11S25N plasmids. Following stable selection with 600 ug/mL of G418 (InvivoGen) through 
multiple passages, the mRFP-Rab11WT /mRFP-Rab11S25N expressing HEK293 cells were 
transiently transfected with MYiAβ1-42. HEK293 cells were grown in DMEM (supplemented with 
10% FBS and 5% penicillin-streptomycin). 
 
3.2.2 Plasmids and cloning strategy  
Cloning of the MYiAβ1-42 expression vector was accomplished by RT-PCR amplification 
of HEK293 derived cDNA followed by cloning into PCR2.1 using the TOPO TA cloning Kit 
(Invitrogen). Subsequently, subcloning of the digested insert was ligated into the digested 
pEYFP-N1 vector (Clontech). The pLenti-EF1a-GFP-2A-Puro vector was kindly provided by the 
laboratory of Dr. Keith R. Johnson. Following PCR amplification of the sequence corresponding 
to Aβ1-42 the insert was similarly cloned into the pLenti-EF1a-GFP-2A-Puro vector. The high titer 
generation of the recombinant lentivirus was performed by the Viral Vector Core Facility at the 
University of Iowa Carver College of Medicine. The resulting virus was employed in the 
transduction of HEK293 and primary rat hippocampal neuronal cells (DIV17).  
 
3.2.3 Western Blotting 
Cells were lysed with RIPA buffer supplemented with cOmplete protease inhibitor 
cocktail (Roche), 8 mM sodium fluoride, 0.5 mM phenylmethylsulfonyl fluoride (PMFS), 1 mM 
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sodium orthovanadate, and 2.5 mM sodium pyrophosphate. Protein was resolved through SDS-
PAGE under denaturing conditions. Transfer on to polyvinylidene difluoride (PVDF) membrane 
was performed and blocked in 5% milk containing PBS or TBS. Subsequent incubation with the 
indicated antibody was done overnight at 4°C. Incubation with HRP-conjugated secondary in 
PBS or TBS containing 3% milk was done for 1 h. Bands were detected using ECL 
chemiluminescence methods (Pierce Thermo Scientific).  
 
3.2.4 Phospho-Flow Cytometry 
Flow cytometry was conducted on the BD LSR II instrument. Subsequent analysis was 
performed using BD FACSDiva 8.0 software for determination of MFI. Briefly, stably expressing 
GFP positive VC or iAβ expressing HEK293 cells were with EGF or BMP-2 for 1 h, fixed with 
4% paraformaldehyde, and permeabilized with ice cold methanol. Subsequently flow cytometry 
was performed following 1 h incubation with 1° antibody, and subsequent 1 h incubation with 
Alexa Fluor 568 conjugated 2° (per abcam indirect flow cytometry protocol). The GFP-positive 
population was then assessed for phospho-ERK 1/2, phospho-EGFR, or phospho-Smad 1/5/8. 
We thank the UNMC Flow Cytometry Research Facility and personnel for their assistance in the 
generation and analysis of this data. 
 
3.2.5 Amyloid Beta Peptide Oligomerization 
The synthetic monomeric β-Amyloid1-42 peptide 
(DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA), purchased from AnaSpec, 
was prepared by dissolving the lyophilized peptide in hexafluoroisoproponol, dried under 
nitrogen steam, and then resuspended in DMSO to a concentration of 10 mM. For subsequent 
preparation of oligomeric forms of the peptide, the 10mM stock was dissolved in DMEM at 25 
µM concentration and incubated at 4°C for 24 h. Alternatively, for fibrillary β-Amyloid formation, 
the 10 mM stock was resuspended in PBS and incubated at 37°C for 24 h while being rotated. 
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Cells, were then pretreated with 1 µM of the soluble or fibrillary extracellular Aβ1-42 24 h prior to 
any subsequent treatment or analysis(Reinke, Gestwicki 2011, Evans, Wisen et al. 2006). 
 
3.2.6 Primary Rat Hippocampal and Cortical Isolation and Culture 
The primary rat hippocampal and cortical neurons were isolated from embryonic day 18 
(E18) rat pups wherein the hippocampi were dissected, triturated, and seeded to poly-L-lysine 
coated plates/coverslips. Likewise, the E18 cortices were similarly isolated and plated. 
Hippocampal and cortical neurons were maintained in Neruobasal® media containing B27 
supplement. Cells were matured and analyzed after 21 days in vitro (DIV21). We thank the Dr. 
Jyothi Arikkath and Li Yuan for their assistance in the generation, isolation, and maintenance of 
these cells(Beaudoin, Lee et al. 2012).  
 
3.2.7 List of Primers 
The following primers were employed for the various expression vector constructs (eurofins):  
 
MYiABF: 
GGATCCGCCACCATGGAACAAAAACTCATCTCAGAAGAGGATCTGGATGC
AGAATTCCGACATGACTC 
MYiABR: AGATCTGACGCTATGACAACACCGCCCACCATGAGTCCAATG 
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3.3 Results 
 
Intracellular Amyloid Beta Expression Results in Impaired Mitogen Signaling 
Persistent neurotrophic support, mediated by MAPK (RAS-RAF-MEK-ERK) pathway 
activation, has been shown to be critical to preserving neuronal cell viability (Mufson, Counts et 
al. 2008). To assess the extent to which MAPK signaling is influenced by iAβ1-42, we have 
generated an intracellular N-terminally MYC-tagged Aβ1-42 expression system. The preliminary 
assessment of the mechanistic and functional impact of iAB expression has on mitogen 
signaling was determined by viral transduction of HEK293 cells with either pLenti-EF1α- GFP-
SV40-Puro vector alone (VC) or pLenti-EF1α- GFP-SV40-Puro Myc-iAβ1-42 (iAB).  
Subsequently, stably selected VC and iAB transduced HEK293 cells were treated with 
vehicle or 50 ng/mL of EGF for 1 h and ERK 1/2 phosphorylation was measured by 
immunoblotting (Figure 3.1.1 A). As anticipated, detection of the MYC-tag could be observed 
only in lanes corresponding to the iAB, but not in the VC samples. Although similar expression 
of total-ERK 1/2 is present in all samples, a robust increase in the ERK 1/2 phosphorylation was 
detected upon EGF stimulation. However, as compared with VC, the iAB transduced cells 
demonstrate a statistically significant 1.67-fold decrease (p < 0.05) in ERK 1/2 phosphorylation 
(Figure 3.1.1 B)  
To better understand how individual cells may respond to EGF stimulation in the context 
of iAB expression, phospho-flow cytometry analysis was performed on VC and iAB transduced 
HEK293 cells (Figure 3.1.2). Following treatment with 50 ng/mL of EGF for 1 h, cells were 
harvested, fixed/permeabilized, and analyzed by indirect flow cytometry. This analysis revealed 
a statistically significant 2.63-fold decrease (p < 0.01) in ERK 1/2 phosphorylation which is 
comparable to the changes measured through immunoblot analysis (Table 3.1.2). 
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Intracellular Amyloid Beta Expression Leads to Relative Decrease in Both Phospho-
EGFR and Total-EGFR Abundance Following EGF Stimulation 
 While an apparent disruption to the mitogen signaling cascade was observed, we further 
assessed the upstream influence that expression of iAB may have on the MAPK pathway. To 
interrogate the upstream effect of iAB, stably selected HEK293 cells transduced with VC or iAB, 
were treated with 50 ng/mL of EGF for 1 h. Next, cells lysates were collected and immunoblot 
assay for total-EGFR and phospho-EGFR was performed (Figure 3.2.1 A). No observable 
differences were noted under unstimulated conditions. However, a relative decrease in both 
total-EGFR and phospho-EGFR were seen upon EGF stimulation. Indeed, a statistically 
significant relative change of 8.3 and 3.3-fold decrease in phospho-EGFR (Ser 1046) and 
phospho-EGFR (Tyr 1068) was observed in the context of iAB expression (Figure 3.2.1 B).  
 Similarly, to analyze the individual cell’s phospho-EGFR abundance, phospho-flow 
cytometry measurement of phospho-EGFR (Tyr 1068) was performed (Figure 3.2.2). From this 
analysis, comparable and statistically significant 1.27-fold decrease in MFI was detected (Table 
3.2.2). Immunoblot and phospho-flow cytometry measurements confirms disruption of upstream 
receptor tyrosine kinase abundance and activity in the presence of iAB. 
 
iAB Expression Leads to Relative Increase in BMP-2 Dependent Smad 1/5/8 
Phosphorylation 
To orchestrate the complex processes of neurogenesis, differentiation, and maintaining 
neuronal cell viability, a delicate balance between mitogenic and morphogenetic signaling is 
necessarily maintained. Our preliminary studies revealed mitogenic signaling to be negatively 
influenced by iAB expression. To elucidate how morphogenetic signaling may be impacted by 
iAB expression, stably selected VC or iAB HEK293 cells were treated with vehicle or 100 ng/mL 
of rh-BMP2 for 1 h. Subsequently, BMP-2 dependent phosphorylation of receptor Smad 1/5/8 
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was assessed by immunoblotting. Although comparable amounts of total-Smad 1/5/8 was 
observed under both treated and untreated conditions, an increase in phospho-Smad 1/5/8 
upon rh-BMP2 could be easily discerned (Figure 3.3.1 A). However, in the background of iAB 
expression, a statistically significant (p < 0.05) 1.8-fold increase in Smad 1/5/8 phosphorylation 
was detected (Figure 3.3.1 B).  
Further analysis of single cell populations by phospho-flow analysis was performed as 
previously described (Figure 3.3.1). This secondary analysis yielded a comparable and 
statistically significant 4.2-fold increase in the receptor Smad 1/5/8 phosphorylation (Table 
3.3.2). Foremost, these findings demonstrate the expression of iAB results in sensitization to rh-
BMP2 dependent morphogen signaling and further suggests a pathophysiological role for iAB 
disruption of the mitogen:morphogen signaling axis.  
 
Differential Influence of Intracellular Aβ1-42 and Extracellular Aβ1-42 on Mitogen Signaling 
While the pathophysiological features of Aβ1-42 have been largely attributed to the 
extracellular activity, here we contrast the intracellular and extracellular isoforms of Aβ1-42 and 
assess their relative impact on the MAPK pathway. While neither the pLenti-EF1α- GFP-SV40-
Puro construct nor the amyloid beta peptide harbor a signal peptide that may direct this protein 
for extracellular deposition, we have confirmed the intracellularly restricted localization. To do 
this, both the cultured supernatant and the total lysates of VC and iAB HEK293 cells were 
screened by immunoblotting for the presence of the MYC-tagged iAB. As show, the presence of 
the MYC-tagged iAB was absent in the supernatant fraction, but was present in the total cell 
lysate indicating its intracellularly restricted localization (Figure 3.4.1). 
The extracellular isoform of Aβ1-42 (eAβ1-42) has been shown to undergo varying degrees 
of quaternary organization resulting in its oligomerization and fibrillization. Furthermore, 
monomeric, oligomeric, and fibrillary forms of the eAβ1-42 have been proposed to harbor 
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pathophysiological roles in Alzheimer’s disease. Following the generation of the various 
isoforms the products were run on 15% SDS PAGE gel and stained with coomassie brilliant 
blue and Sypro ® Ruby. The staining of these products revealed the successful generation of 
monomeric/oligomeric (Figure 3.4.2 A) and fibrillary (Figure 3.4.2 B) isoforms of the eAβ1-42. 
These pooled monomeric, oligomeric, and fibrillary products (M/O/F) were then employed for 
further analysis of the mitogen signaling activity in the presence and absence of iAB (Figure 
3.4.2 C).  
 Subsequent determination of the impact of eAβ1-42 on MAPK signaling was performed by 
pre-treating VC and iAB HEK293 cells with the M/O/F cocktail. Following a 24 h incubation with 
M/O/F eAβ1-42 products, VC and iAB cells were stimulated with 50 ng/mL of EGF for 1 h before 
lysates were collected and analyzed by immunoblotting. As shown, the presence of eAβ1-42 had 
minimal influence on the VC sensitivity to EGF. However, M/O/F pre-treatment in the context of 
iAB expression led to a statistically significant (p < 0.05) synergistic 2.63-fold reduction in the 
ERK 1/2 phosphorylation (Figure 3.4.3 A & B).  
 
Cytosolic and ER Stress Response Assessment Upon iAB Expression  
 To exclude cytosolic or ER stress as confounding variables that may affect our assay of 
MAPK pathway activation, markers for cytosolic and ER stress response were measured in the 
context of VC or iAB HEK293 cell transduction. Immunoblot measurement of heat shock 
proteins (HSP60 and HSP70) did not yield any notable differences in cytosolic stress response 
(Figure 3.5.1 A). As a positive control for cytosolic stress response, the proteasome inhibitor 
MG-132, was employed.  
 To evaluate whether ER stress response was activated in the context of iAB expression, 
alternative splicing of XBP1 was measured by RT-PCR. As a positive control for ER stress 
induction and XBP1 alternative splicing, VC or iAB cells were treated with tunicamycin (2 µg/mL) 
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for the time indicated. While tunicamycin treated VC and iAB cells show a shift and 
accumulation of the XBP1 splice product, there is no such shift observed in the untreated VC or 
iAB cells (Figure 3.5.1 B). These results indicate that cytosolic and ER stress response are 
negligibly affected by the ectopic expression of the iAB peptide and are therefore unlikely to 
influence our observations regarding MAPK activity. 
 
PLX4032 Rescue of Diminished ERK 1/2 Phosphorylation 
 Our preliminary results suggested that MAPK pathway disruption was being initiated 
early in the MAPK signaling cascade. To circumvent and rescue this effect, we employed the 
mitogen signaling activator, PLX4032. Thus, VC and iAB HEK293 cells were pre-treated with 
PLX4032 (0.1 µM) for 30 min prior to incubation with EGF for 1 h. Lysates were then collected 
and total-ERK 1/2, phospho-ERK 1/2, and phospho-c-RAF were measured by immunoblotting 
(Figure 3.6.1 A).  Induction of ERK 1/2 phosphorylation can be observed in both VC and iAB 
EGF treated cells. However, in contrast to previous observations, no statistical difference (p > 
0.05) can be observed in PLX4032 pretreated VC and iAB cells stimulated with EGF (Figure 
3.6.1 B).   
 Subsequent analysis by phospho-flow cytometry was employed and phosho-ERK 1/2 
levels were determined (Figure 3.6.2). This secondary analysis confirmed the enhancement of 
phospho-ERK 1/2 levels when cells were treated with PLX4032 and EGF stimulated. Indeed, a 
statistically significant (p < 0.05) 1.47-fold increase in the phospho-ERK 1/2 MFI was observed 
(Table 3.6.2). Combined, these results suggest both a pathophysiological role of iAB and a 
means of restoring this dysfunctional arm of the mitogen/morphogenetic signaling axis. 
 
In Vitro Maturation and Characterization of Primary Rat Cortical and Hippocampal 
Neurons 
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 While the HEK293 cells allowed us to understand fundamental aspects of the functional 
and mechanistic implications involving iAB expression, we have employed an alternative model 
to broaden the significance of these observations in a more biologically relevant context. To 
accomplish this, primary cortical and hippocampal neurons were isolated from embryonic day 
18 (E18) rat pups (Beaudoin, Lee et al. 2012). Furthermore, to achieve a maturation state most 
consistent with that observed in the context of neurodegenerative disease, the primary cortical 
and hippocampal neuronal cells were subsequently matured in vitro for 21 days prior to any 
subsequent analysis (Figure 3.7.1). As shown, the in vitro maturation of the neuronal cells 
allows for the axonal and dendritic outgrowth and the establishment and maintenance of basic 
synaptic networks. 
 Furthermore, in addition to basic dendritic and axonal maturation, neuronal cells are 
almost unfailingly associated with astrocytic that provide support and protection in vivo and in 
vitro. Consequently, the primary neuronal cell culture employed is a co-culture of both primary 
cortical or hippocampal neurons as well as astrocytes. To understand the degree to which each 
population is represented, confocal microscopy was performed on DIV21 hippocampal cultures. 
As shown, ActinGreen TM staining reveals both the dendritic features of the cultured neurons as 
well as the actin cytoskeletal of the astrocytes. In contrast, GFAP (red) stained astrocytes are of 
present, but of lower abundance in the co-culture (Figure 3.7.2). 
 To assess how signaling may be influenced by iAB in cells of neuronal lineage, it was 
first necessary to characterize the relative sensitivity of both cortical and hippocampal neurons 
to relevant cytokines and growth factors. Consequently, cortical and hippocampal neuronal 
cultures (DIV21) were treated with, Bone Morphogenetic Protein 2 (rh-BMP2), Nerve Growth 
Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF), or Epidermal Growth Factor (EGF) 
and their ability to activate their respective pathways was subsequently measured by 
immunoblotting.   
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 In our characterization of primary hippocampal and cortical neuronal sensitivity to rh-
BMP2, both 100 ng/mL and 200 ng/mL concentrations were used for the 1 h treatment of 
cultures followed by isolation and assay of the cell lysates. Both concentrations of rh-BMP2 
were capable of inducing receptor Smad 1/5/8 phosphorylation (Figure 3.8.1). However, 
hippocampal cells demonstrated an increased sensitivity as compared to cortical neuronal 
samples. Furthermore, the 30-min pretreatment of the hippocampal and cortical cultures with 
dorsomorphin (15 µM) was sufficient to abrogate Smad 1/5/8 phosphorylation.  
 Next, we assessed the hippocampal and cortical neuronal sensitivity to NGF in the 
presence and absence of PLX4032 (Figure 3.8.2). Although hippocampal cells showed robust 
ERK 1/2 phosphorylation in response to NGF, the cortical cells did not respond to NGF 
stimulation. Furthermore, in the presence of PLX4032, an observable increase in the ERK 1/2 
phosphorylation could be observed relative to hippocampal cells treated with NGF and DMSO.  
 Similarly, we investigated the relative sensitivity of hippocampal and cortical cells to EGF 
and BDNF with and without PLX4032 pretreatment (Figure 3.8.3). Interestingly, the 
hippocampal cells again showed a much greater degree of ERK 1/2 phosphorylation in 
response to either EGF or BDNF as compared to the cortical cultures. Furthermore, 
hippocampal cells pretreated with PLX4032 showed a greater abundance of phosho-ERK 1/2 
levels as compared to cells pretreated with DMSO alone. Combined these results suggest a 
greater sensitivity to growth factor and cytokine signaling in hippocampal cells relative to that of 
cortical cells. Furthermore, PLX4032 can be employed similarly in neuronal cell cultures with 
comparable activation of MAPK pathway. 
 
iAB Expression Results in Reduced Brain-Derived Neurotrophic Factor (BDNF) Mediated 
ERK 1/2 Phosphorylation of Primary Rat Hippocampal Cells and is Rescued with 
PLX4032 
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Based upon our preliminary findings regarding the preferential sensitivity of hippocampal 
neurons to NGF, EGF, and BDNF treatment and the predisposition of the hippocampus to 
neurodegeneration in Alzheimer’s disease, we further sought to investigate the impact iAB may 
have on the mitogen signaling pathway using hippocampal neuronal cultures (Mu, Gage 2011). 
To understand how iAB may influence the mitogen signaling activity in hippocampal neurons, 
cultures were transduced with either the VC or with iAB at DIV17. On DIV21, cells were either 
pretreated with DMSO or PLX4032 (0.1 µM) for 30 min before being treated with BDNF 50 
ng/mL for 1 h. Subsequently lysates were collected and the abundance of ERK 1/2 
phosphorylation was determined by immunoblotting (Figure 3.9.1). Consistent with our previous 
studies performed using HEK293 cells, there was a statistically significant (p < 0.01) 1.61-fold 
decrease in ERK 1/2 phosphorylation was observed (Figure 3.9.2). However, in the presence of 
PLX4032 pretreatment, the decrease in ERK 1/2 phosphorylation was attenuated and no 
significant (p > 0.05) difference between VC and PLX4032 pretreated iAB phospho-ERK 1/2 
intensity could be discerned. Thus, iAB negatively influences the mitogen signaling strength in 
hippocampal cells and this disruption can be partially rescued using PLX4032 as a mitogen 
signaling enhancer.  
 
Altering the Endocytic Trafficking Itinerary Leads to Increased Phospho-ERK 1/2 
Intensity in iAB Expression Cells 
Following ligand activation of rector tyrosine kinases, the receptor ligand/receptor 
oligomeric complex undergoes rapid endocytosis. Subsequently, the complex is shuttled within 
the cells through fast or slow recycling pathways that may result its lysosomal degradation or 
trafficking to the plasma membrane where it can further participate in iterations of signal 
transduction (Roepstorff, Grandal et al. 2009). The extent to which these pathways are utilized 
can significantly influence the intensity and duration of growth factor signaling. We have 
observed a statistically significant reduction in the abundance of both the total and phospho-
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EGFR (Tyr 1063 & Ser 1068) in MYiAB transfected HEK293 cells following EGF stimulation 
(Figure 3.2.1 & Figure 3.2.2). However, the abundance of total-EGFR in unaffected in the 
absence of EGF stimulation thereby suggesting that following receptor mediated endocytosis 
the EGFR stability is being impacted by MYiAB expression. To further test this, we have 
cotransfected either wild-type Rab11a or a dominant negative mutant Rab11aS25N to inhibit the 
extent to which the slow trafficking pathway may be utilized. As show, in the context of the 
Rab11aS25N expression, there is a robust increase in phospho-ERK 1/2 intensity (Figure 3.10.1). 
This the increase in ERK 1/2 phosphorylation upon disruption of the slow trafficking pathway 
suggests that the slow endocytic recycling pathway may predominate along with trafficking to 
the lysosomal.  
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3.4 Discussion 
 As the demographics of our population continue to shift in age, we are at an increasing 
likelihood of encountering a corresponding rise in the incidence of AD. While currently, one in 
nine Americans over the age 65 and older will be afflicted with AD, this number is expected to 
double by the year 2050 (Alzheimer's Association 2016). Despite the ever-increasing health and 
socioeconomic threat this disease poses to our society, there has been only modest success in 
improving cognitive function or reducing the neurodegenerative effects of this illness. While the 
central features of AD have been recognized for over a century, there remains a great deal to 
be learned about the pathophysiological properties of amyloid beta mediated disease.  
Although a hallmark of AD, the significance of the amyloid beta peptide and its 
fundamental pathological mechanism has remained unsettled. However, recent findings have 
revealed a subtle and previously unexplored aspect of amyloid beta expression wherein amyloid 
beta is not only deposited extracellularly, but also found in the intracellular compartment as well. 
The appearance and accumulation of iAβ1-42 prior to the characteristic extracellular deposition of 
parenchymal neuritic plaques has compelled us to explore the pathophysiological implications of 
increased iAβ1-42 expression. 
Investigation into the etiology of hereditary early onset Alzheimer’s disease (EOAD) has 
provided further evidence for the pathophysiological significance of the intracellular 
accumulation of the long-isoform of Aβ expression. In particular, EOAD patients harboring APP 
or presenilin 1 (PS1) mutations display a shift in production of the short (40 a.a.) isomer to long 
(42 a.a.) isomer resulting in a corresponding shift in the Aβ40/42 proportions (Borchelt, 
Thinakaran et al. 1996, Haass, Hung et al. 1994). Furthermore, in addition to stoichiometric 
expansion of long isoform production, triple-transgenic mouse models of AD 
(APPsweXPS1M146VXTauP301L) have implicated the long isoform (Aβ1-42) as the predominant 
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intracellular representative (Oddo, Caccamo et al. 2003). Thus, there appears to be a 
compelling correlation between iAβ1-42 and the onset and progression of AD. 
As previously described, neuronal cells rely extensively on the continuous balance of 
positive and negative environmental signaling cues to preserve and promote cell viability (Yuen, 
Howe et al. 1996, Schinder, Berninger et al. 2000). To understand how iAβ1-42 may affect this 
delicate equilibrium. We have employed an in vitro iAB expression system to biochemically 
investigate the potential dysregulation of two critically important signaling pathways. Namely, 
the mitogen (MAPK) and morphogen signaling pathways. These well characterized signal 
transduction modalities are employed by a broad range of molecules used to elicit gene 
activation in response to extracellular ligands. However, we have focused our investigation on 
ligand mediated and subsequent signaling cascades that have been shown to be most 
important in maintaining neuronal homeostasis. 
Our evaluation of mitogen signaling was performed by using EGF or BDNF in both 
HEK293 cells and in primary rat hippocampal neurons respectively. As a biological readout of 
the sensitivity of these cells to mitogen pathway activation we have used the mitogen-activated 
protein kinase ERK 1/2 phosphorylation. This particular MAPK has been most closely 
associated with NGF, BDNF, and EGF mediated activation of tyrosine receptor kinases TrkA, 
TrkB, and EGFR and subsequent pro-survival signaling (Alderson, Alterman et al. 1990, Allen, 
MacGowan et al. 1991). Our investigation of the iAB mediated alterations to this arm of the 
mitogenic/morphogenetic signaling axis has revealed a statistically significant decline in the 
responsiveness in both HEK293 and primary rat hippocampal neurons in the context of iAB 
expression.  
While, the aforementioned mitogenic signals are critical positive regulators of cell 
viability, morphogenetic signaling cues often play an opposing role. During neuronal 
development, the morphogenetic family of signaling molecules (i.e. BMP-2 and BMP-4) are 
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crucial to promoting differentiation and inducing programmed cell death. Furthermore, BMP-2 or 
BMP-4 dependent BMPR1a activation and subsequent receptor Smad 1/5/8 phosphorylation 
has been demonstrated to induce neurotrophic addiction in neural precursor cells and rendering 
them more sensitive to reduced neurotrophic support (Gambaro, Aberdam et al. 2006, Pisano, 
Colon-Hastings et al. 2000). Upon examination of this signaling modality we have observed an 
upregulation in the relative Smad 1/5/8 phosphorylation intensities of exogenously expressing 
iAB HEK293 cells. Combined with the apparent decrease in MAPK signaling, an increase in 
morphogen sensitivity may produce a deleterious outcome similar to programmed cell death 
initiated during neuronal development. 
To gain further mechanistic insight into the underlying source of dysregulated signaling, 
we have focused our efforts on resolving the aberrant mitogenic response. Interestingly, our 
study of the EGF receptor tyrosine kinase status has revealed the abundance of total-EGFR to 
be unaltered in either VC or iAB transduced HEK293 cells. In contrast, phospho-EGFR and 
total-EGFR was found to be relatively diminished in iAB transduced HEK293 cells upon 
treatment with EGF. The significance of this subtle distinction suggests that the decrease in 
downstream ERK 1/2 phosphorylation may be due to a change in the post-endocytic receptor 
stability.    
While many variables may be at play, the most straightforward interpretation of these 
findings are that aberrant signaling is, in part, an effect of the mass action kinetics whereby an 
iAB mediated reduction in EGFR concentration on the cell surface leads to decreased 
downstream signaling following receptor mediated endocytosis (RME) and subsequent 
retrograde transport. Both posttranslational modifications (PTM) and Rab GTPase-mediated 
trafficking affect the fate of endocytosed cargo (Ascano, Bodmer et al. 2012, Cosker, Segal 
2014). Rab11a is most frequently recognized as a marker for the endosomal recycling complex 
(ERC) and slow anterograde trafficking. Consistent with comparable findings employing 
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dominant negative Rab7, we have observed a corresponding rescue of ERK1/2 phosphorylation 
upon transfection with the dominant negative RFP-tagged Rab11S25N plasmid (Saxena, Bucci et 
al. 2005). Thus, altering the kinetics of endocytic transport through exogenous MYiAβ1-42 
expression or by rescue with dominant negative Rab11S25N, implicates endocytic transport as 
the functional point of signaling dysregulation. 
With the insight gained from these preliminary experiments in mind, we subsequently 
identified a strategy that would most likely restore the negative effects on mitogen signaling 
observed upon iAB expression. For this purpose, we have utilized PLX4032 as a novel 
enhancer of MAPK signaling. Although, this small molecule inhibitor is an effective therapeutic 
tool used for the treatment of melanoma patients harboring BRAFV600E activating mutations, a 
paradoxical activation of the MAPK pathway is observed in a BRAFWT genetic background. 
Indeed, at low concentrations, PLX4032 induces heterodimerization with CRAF and enhanced 
MAPK signaling upon growth factor stimulation (i.e. EGF or BDNF) has been frequently 
observed (Halaban, Zhang et al. 2010). When employed in combination with EGF or BDNF 
stimulation in either HEK293 or primary rat hippocampal neurons, the pretreatment with 
PLX4032 let to the restoration of the ERK 1/2 phosphorylation.  
While our efforts in this study were principally focused on the effects of iAβ1-42 expression 
on MAPK activity, further secondary effects may also result from changes to the mitogen 
signaling intensity. In addition to neurodegeneration, cognitive impairment is pathognomonic for 
AD. While loss of neuronal density must certainly significantly contribute, several neurochemical 
changes occur that impact cognitive decline. In particular, the neurotransmitter acetylcholine 
(ACh) has been found to be deficient in AD patients (Caccamo, Oddo et al. 2006). Furthermore, 
it has been previously reported that NGF stimulation can induce choline acetyltransferase 
expression and increase the conversion of choline to ACh (Heumann, Schwab et al. 1984). 
Consequently, restoration of NGF mediated signaling may serve to improve cognitive function in 
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a comparable way existing cholinesterase inhibitors serve to increase the pools of ACh (i.e. 
Rivastigmine or Donepezil). 
In addition to the extracellular and intracellular amyloid beta accumulation, development 
of neurofibrillary tangles consisting of hyper-phosphorylated Tau proteins are hallmark 
developments in AD. Although, a clear pathophysiological relationship between the appearance 
of amyloid beta peptide and Tau phosphorylation has yet to be clearly elucidated several 
kinases have been implicated in Tau phosphorylation. In particular, glycogen synthase kinase-3 
(GSK-3β) has been shown to participate in Tau phosphorylation (Pei, Braak et al. 1999). While 
regulation of GSK-3β is complex, growth factor signaling is a central part in maintaining GSK-3β 
in an inactive state. Thus, in the presence of growth factor stimulation (i.e. EGF, NGF, or BDNF) 
inactive GSK-3β will be prevented from participating in Tau phosphorylation. However, loss of 
growth factor signaling intensity, as we have observed in the context of iAB expression, may 
lead to the activation of GSK-3β and subsequent increase in Tau phosphorylation (Frame, 
Cohen 2001).   
Owing to the inherent cellular phylogenetic specialization and integrated network 
biology, neuronal cells may be particularly vulnerable to fluctuations in mitogen/morphogen 
signaling. As a proof of concept, we have employed an iAB expression system which has 
permitted us to model a cryptic yet integral feature of AD molecular biology. Furthermore, the 
iAβ1-42 mediated dysregulation can be partially rescued through the use of either PLX4032 
(MAPK activator) to restore mitogen signaling homeostasis. Although many subtleties regarding 
this novel shade of amyloid beta mediated pathology remain to be investigated, our findings 
suggest a role for intracellular amyloid beta expression and may also recommend a strategy for 
targeting the pathological effects of iAβ1-42 through restoration of the mitogen/morphogen 
signaling axis. 
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Figure 3.1.1 
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Figure 3.1.1 iAB Expression Leads to Diminished EGF-Dependent ERK1/2 
Phosphorylation (A) Immunoblot of phospho-ERK 1/2, total-ERK 1/2, and MYC-Tag in vector 
(VC) or iAβ1-42 (iAB) transduced HEK293 cells following EGF stimulation. Decreased EGF 
dependent phospho-ERK 1/2 induction observed in iAB transduced cells relative to VC (B) Plot 
of relative densitometry analysis of phospho-ERK 1/2 biological replicates with data shown as 
mean ± SE (n=3) with statistical significance indicated (p < 0.05). Two-dimensional gel 
transformation of phospho-ERK 1/2 intensities performed and shown as histogram above. Beta-
Actin used as loading control. 
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Figure 3.1.2 
Table 3.1.2 Phospho-Flow Cytometry of ERK 1/2  
 MFI Average MFI Fold-Change p-value 
VC1 10388 
9683.7 ± 972.7 
2.86-Fold  
Decrease 
0.002616 
VC2 7817 
VC3 10846 
iAβ1 3462 
3378.0 ± 58.3 iAβ2 3406 
iAβ3 3266 
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Figure 3.1.2 Phospho-Flow Cytometry Analysis Reveals Diminished EGF-Dependent 
ERK1/2 Phosphorylation Upon iAβ1-42 Expression Histogram of phospho-flow cytometry 
analysis of EGF treated VC (gray) or iAβ1-42 (black) transduced HEK293 cells. A shift in the MFI 
of iAB relative to VC reflecting a decrease in EGF dependent ERK 1/2 phosphorylation.  Data 
table of replicate analysis shown as mean ± SE (n=3) of the MFI with fold-change and statistical 
significance indicated.  
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Figure 3.2.1 
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Figure 3.2.1 iAβ1-42 Expression Leads to Reduced Total-EGFR and Phospho-EGFR 
Abundance Following EGF Stimulation (A) Immunoblot of Total-EGFR, Phospho-EGFR (Ser 
1046), and Phospho-EGFR (Tyr 1068) in vector (VC) or iAβ1-42 (iAB) transduced HEK293 cells 
following EGF stimulation. Decreased EGFR phosphorylation observed in iAB transduced 
relative to VC (B) Plot of relative densitometry analysis of the EGFR Ser 1046 and Tyr 1068 
phosphorylation in biological replicates with data shown as mean ± SE (n=3) and statistical 
significance indicated (p < 0.01). Beta-Actin used as loading control. 
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Figure 3.2.2 
 
Table 3.2.2 Phospho-Flow Cytometry of EGFR  
 MFI Average MFI Fold-Change p-value 
VC1 2687 
2640 ± 239.7 
1.26-Fold 
Decrease 
0.0049 
VC2 2358 
VC3 2580 
VC4 2935 
iAβ1 2057 
2077.5 ± 101.3 
iAβ2 1978 
iAβ3 2056 
iAβ4 2219 
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Figure 3.2.2 Phospho-Flow Cytometry Analysis of EGFR phosphorylation (Tyr 1068) 
Demonstrates Decreased Intensity Upon iAβ1-42 Expression Histogram of phospho-flow 
cytometry analysis of EGF treated VC (gray) or iAβ1-42 (black) transduced HEK293 cells. Shift in 
the MFI of iAB transduced cells relative to the VC reflects a decrease in the phospho-EGFR (Tyr 
1068) abundance. Data table of replicate analysis shown as mean ± SE (n=3) of the MFI with 
fold-change and statistical significance indicated.  
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Figure 3.3.1 
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Figure 3.3.1 iAβ1-42 Expression Leads to Relative Increase in BMP-2 Dependent Smad 
1/5/8 Phosphorylation (A) Immunoblot of the phospho-Smad 1/5/8 and total-Smad 1/5/8 in 
vector (VC) or iAβ1-42 (iAB) transduced HEK293 cells following rh-BMP2 stimulation. An increase 
in the rh-BMP2 dependent Smad 1/5/8 phosphorylation can be observed in the iAB transduced 
cells relative to VC. (B) Plot of relative densitometry analysis of phospho-Smad 1/5/8 biological 
replicates with data shown as mean ± SE (n=3) with statistical significance indicated (p < 0.05). 
Two-dimensional gel transformation of phospho-Smad 1/5/8 intensities performed and shown as 
histogram above. Beta-Actin used as loading control. 
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Figure 3.3.2 
 
Table 3.3.2 Phospho-Flow Cytometry of Smad 1/5/8  
 
 MFI Average MFI Fold-Change p-value 
VC1 1927 
1642.8 ± 227.8 
4.2-Fold 
Increase 
0.002 
VC2 1685 
VC3 986 
VC4 1973 
iAβ1 8752 
6900.3 ± 1024.0 
iAβ2 3992 
iAβ3 7690 
iAβ4 7167 
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Figure 3.3.2 Phospho-Flow Cytometry Analysis Shows Increased BMP-2 Mediated Smad 
1/5/8 Phosphorylation Upon iAβ1-42 Expression Histogram of phospho-flow cytometry 
analysis of rh-BMP2 treated VC (gray) or iAβ1-42 (black) transduced HEK293 cells. A positive 
shift in iAB transduced cells relative to the VC can be seen indicating an increase in the 
abundance of phospho-Smad 1/5/8. Data table of replicate analysis shown as mean ± SE (n=3) 
of the MFI with fold-change and statistical significance indicated. Dixon’s outlier analysis was 
performed on the replicates and there are not outliers within the dataset that should be excluded 
(p > 0.05). 
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Figure 3.4.1 
 
Figure 3.4.1 Confirmation of the iAβ1-42 Expression and Intracellularly Restricted 
Localization (A) Immunoblot of the concentrated supernatant and the total lysates of vector 
(VC) or iAβ1-42 (iAB) transduced HEK293 cells for MYC-Tagged iAβ1-42 expression. The absence 
of expression in the samples obtained from the cultured supernatant confirms it intracellular 
retention. Beta-Actin employed as loading control. (B) Coomassie brilliant blue stained, 12% 
SDS PAGE gel, of both concentrated supernatant and total cell lysates in VC and iAβ 
transduced cells.  
 
 
 
 
 
 
VC iAβ1-42 VC iAβ1-42
Supernatant Total-Lysate
MYC-Tag
Actin
A 
B 
111 
 
Figure 3.4.2 
 
Figure 3.4.2 Validation of Extracellular Aβ1-42 (eAβ1-42) Oligomer and Fibrillar Organization 
(A) Coomassie brilliant blue stained, 15% SDS PAGE gel, of eAβ1-42 showing the varying 
quaternary organization states under the aggregation conditions indicated. (B) Sypro ® Ruby 
stained, 15% SDS PAGE gel, of eAβ1-42 revealing the higher order quaternary organization 
states under conditions indicated. (C) Schematic representing the general treatment and eAβ1-42 
assay conditions employed. 
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Figure 3.4.3 
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Figure 3.4.3 Immunoblot Assessment of the Role of Extracellular Aβ1-42 (eAβ1-42) Reveals 
Synergistic Decrease in ERK 1/2 Phosphorylation (A) Immunoblot of the phospho-ERK 1/2 
and total-ERK 1/2 of vector (VC) or iAβ1-42 (iAB) transduced HEK293 cells following 24 h 
pretreatment with monomeric/oligomeric/fibrillary (M/O/F) eAβ1-42 and subsequent EGF 
stimulation. No differences in EGF responsiveness observed in the VC DMSO or M/O/F treated 
samples. Decreased ERK 1/2 phosphorylation seen in iAB transduced cells treated with eAβ1-42 
relative iAB transduced cells treated with DMSO alone. Beta-Actin employed as loading control. 
(B) Plot of relative densitometry analysis of phospho-ERK 1/2 intensity in VC or iAB after 
treatment with DMSO or M/O/F with biological replicates with data shown as mean ± SE (n=3) 
and statistical significance indicated.  
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Figure 3.5.1 
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Figure 3.5.1 Cytosolic and ER Stress Response is Minimally Altered Upon iAβ1-42 
Expression (A) Assessment of cytosolic stress response was measured by immunoblot of 
HSP60 and HSP70 in vector (VC) or iAβ1-42 (iAB) transduced HEK293 cells. MG-132 treated 
vector (VC) or iAβ1-42 (iAB) transduced HEK293 cells were employed as a positive control for 
cytosolic stress response. No change in HSP60 or HSP70 observed indicating the cytosolic 
stress response is not activated as a consequence of iAB expression. Beta-Actin also probed 
and run on separate gel. (B) Evaluation of ER stress response was performed by RT-PCR of 
the alternatively spliced XBP1 transcript in VC or iAB transduced HEK293 cells. Tunicamycin 
treated VC or iAB transduced HEK293 were employed as a positive control for ER stress 
response induced splicing of XBP1. Splicing observed upon treatment with the positive control 
(Tunicamycin), but not in the VC or iAB DMSO treated samples indicating the ER stress 
response is not activated due to iAB expression. The ACTB housekeeping transcript was used 
as a loading control. 
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Figure 3.6.1 
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Figure 3.6.1 PLX4032 Rescue of iAβ1-42 Mediated Attenuation of ERK 1/2 Phosphorylation 
(A) Immunoblot for phospho-ERK 1/2, total-ERK 1/2, and phospho-c-RAF (ser 259) in vector 
(VC) or iAβ1-42 (iAB) transduced HEK293 cells following pretreatment with PLX4032 (30 min) 
and subsequent vehicle or EGF stimulation. Two-dimensional gel transformation of phospho-
ERK 1/2 intensities performed and shown as histogram above. Rescue of ERK 1/2 
phosphorylation seen upon treatment with PLX4032. Beta-Actin used as loading control. (B) 
Graph of the relative densitometry analysis of biological replicates with data shown as mean ± 
SE (n=3) with statistical significance indicated (p > 0.05). 
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Figure 3.6.2 
Table 3.6.2 Phospho-Flow Cytometry of ERK 1/2 Following PLX4032 Treatment 
 MFI Average MFI Fold-Change p-value 
VC1 21641 
24297.3 ± 2691.4 
1.47-Fold 
Increase 
0.04757 
VC2 21571 
VC3 29680 
iAβ1 31794 
35720.3 ± 3017.2 iAβ2 33715 
iAβ3 41652 
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Figure 3.6.2 Phospho-Flow Cytometry Evaluation of PLX4032 Restoration of ERK 1/2 
Phosphorylation in iAβ1-42 Transduced Cells (A) Histogram of the phospho-flow cytometry 
measurement of EGF treated VC (gray) or iAβ1-42 (black) transduced HEK293 cells for ERK 1/2 
phosphorylation. Positive shift in the MFI of iAB transduced cells show reflects the increase in 
EGF dependent and PLX4032 mediated ERK 1/2 phosphorylation.  Data table of replicate 
analysis shown as mean ± SE (n=3) of the MFI with fold-change and statistical significance 
indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
120 
 
Figure 3.7.1 
 
Figure 3.7.1 In Vitro Maturation of Primary Rat Hippocampal (HPC) Neurons Phase 
Contrast images of the in vitro maturation of primary HPC neuronal cells under 10x, 20x, and 
40x magnification taken at DIV3, DIV12, DIV17, and DIV21 respectively. Subsequent 
Transductions or transfections were performed at DIV17 and lysates collected on DIV21. 
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Figure 3.7.2  
HPC DIV21
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Figure 3.7.2 Confocal Microscopic Characterization of the Primary Rat Hippocampal Co-
Culture of Neuronal and Astrocyte Cells (DIV21) Confocal Images of DIV21 HPC co-cultures 
stained with ActinGreen TM, astrocyte marker GFAP (Red), and DAPI nuclear stain (Blue). 
Images were taken at 63x magnification with representative images shown.  
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Figure 3.8.1 
 
Figure 3.8.1 Characterization of Primary Rat Hippocampal and Cortical Neurons (DIV21) 
Sensitivity to rh-BMP2 Immunoblot of phospho-Smad 1/5/8 and total-Smad 1/5/8 of DIV21 
primary HPC and CTC cells following treatment with rh-BMP2 alone or in combination with the 
BMP-2 receptor inhibitor (Dorsomorphin). Increased hippocampal responsiveness observed 
relative to cortical samples. Beta-Actin utilized as loading control. 
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Figure 3.8.2 
 
Figure 3.8.2 Biochemical Characterization of Primary Rat Hippocampal and Cortical 
Neurons (DIV21) Sensitivity to Nerve Growth Factor (NGF) Immunoblot of phospho-ERK 1/2 
and total-ERK1/2 of DIV21 primary HPC and CTC cells following treatment with DMSO, NGF 
alone, or NGF in combination with PLX4032. Increased hippocampal sensitivity relative to the 
cortical derived samples. Pre-treatment with PLX4032 modestly increased the NGF dependent 
ERK 1/2 phosphorylation. Beta-Actin used as loading control. 
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Figure 3.8.3 
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Figure 3.8.3 Biochemical Determination of Primary Rat Hippocampal and Cortical 
Neurons (DIV21) Sensitivity to Epidermal Growth Factor (EGF) and Brain-Derived 
Neurotrophic Factor (BDNF) Immunoblot of phosphorylated and total ERK 1/2, EGFR (Tyr 
1068), AKT (Ser 473 & Thr 308), and p38 of DIV21 primary HPC and CTC cells following 
treatment with DMSO, EGF or BDNF alone, or EGF or BDNF in combination with PLX4032. 
Increased hippocampal sensitivity with PLX4032 pre-treatment leading to modest increase in 
ERK 1/2 phosphorylation in both EGF and BDNF treated samples. Beta-Actin employed as 
loading control. 
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Figure 3.9.1 
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Figure 3.9.1 Reduced Brain-Derived Neurotrophic Factor (BDNF) Mediated ERK 1/2 
Phosphorylation of Primary Rat Hippocampal Cells (HPC) Following iAβ1-42 Expression 
and Rescue with PLX4032 Immunoblot of phospho-ERK 1/2, total-ERK 1/2, and MYC-Tag in 
vector (VC) or iAβ1-42 (iAB) transduced HPC neurons (DIV21) following BDNF stimulation. Myc-
tag observed in the iAB and absent in VC transduced hippocampal cells. Increased ERK 1/2 
phosphorylation observed upon pre-treatment with PLX4032. Two-dimensional gel 
transformation of phospho-ERK 1/2 intensities performed and shown as histogram above. 
Biological replicates performed (n=4). Actin or GAPDH used as loading control. 
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Figure 3.9.2 
 
 
 
 
Figure 3.9.2 Plot of Diminished Brain-Derived Neurotrophic Factor (BDNF) Mediated ERK 
1/2 Phosphorylation of Primary Rat Hippocampal Cells Following iAB Expression and 
Rescue with PLX4032 Plot of relative densitometry analysis of phospho-ERK 1/2 biological 
replicates with data shown as mean ± SE (n=3) with statistical significance indicated (p < 0.01). 
Decreased phospho-ERK 1/2 observed in iAB transduced cells and restored upon pre-treatment 
with PLX4032. 
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Figure 3.10.1 
 
Figure 3.10.1 Alteration of Slow Endocytic Recycling of EGFR Leads to Increased EGF 
Dependent ERK 1/2 Phosphorylation Immunoblot of phospho-ERK 1/2, total-ERK 1/2, and 
YFP-Tag in pEYFP-N1 vector (VC) or iAβ1-42 (MYiAB) transfected HEK293 cells cotransfected 
with either wild-type Rab11a or dominant negative mutant Rab11aS25N. Inhibition of slow 
endocytic recycling upon Rab11aS25N expression leads to an increase in EGF dependent ERK 
1/2 phosphorylation. Beta-Actin also probed and run on separate gel. 
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CHAPTER 4 
 
Summary and Conclusions 
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Summary and Conclusions 
The mitogen and morphogen signaling transduction is a key regulator of cell viability, 
proliferation, differentiation, and motility. Dysregulation of these signaling pathways are 
commonly encountered in numerous pathological contexts. While disturbances to the MAPK 
pathway have predictable consequences, the pleiotropic properties of the bone morphogenetic 
superfamily have made interpreting the impact of disturbances to this pathway difficult to 
interpret. The studies performed in this dissertation were undertaken to assess the impact 
dysregulation of the mitogen/morphogen signaling axis has in the context of pancreatic cancer 
and in Alzheimer’s disease. The contrasting phenotypes seen in PC and AD, of 
proliferation/metastasis and neuronal cell death, have shed novel insight into the nuances that 
influence the pathological outcomes from the dysregulation of this pivotal axis. 
 We have employed bone morphogenetic protein 2 (BMP-2), an archetypical BMP 
superfamily member predicted to be upregulated in PC subset, as a model for understanding 
the role of morphogen signaling in PC. Our subsequent investigation has revealed the potential 
for three distinct isoforms to be expressed from the BMP-2 gene locus. Using the HupT3 PC cell 
line, that harbors both activating K-Ras and inactivating p53 mutations, we have assessed the 
impact of the extracellular, intracellular, and long non-coding RNA isoforms. Upon 
overexpression of these isoforms, we found the long non-coding BMP-2 variant to be the most 
potent inducer of EMT markers, migration, motility, and invasion. In contrast, upon 
CRISPR/Cas9 mediated knockdown of the BMP-2 gene cassette there was a profound 
decrease in EMT marker and migration. Interestingly, while expression of the long non-coding 
BMP-2 variant, its reverse compliment, or CRISPR/Cas9 knockdown decreased BMP-2 
expression, only the non-coding expression resulted in changes in the migration and invasive 
potential of these cells. Furthermore, treatment of HupT3 cells with either the extracellular (rh-
BMP2) or overexpression of the intracellular variants did not have an overt effect on the 
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migration of these cells. These observations implicate the long non-coding isoform in mediating 
the oncogenic features. Thus, while BMP-2 has long been treated as a pleiotropic gene, it may 
be more apt consider this as a gene cassette with oncogenic and tumor suppressive isoforms.  
Therefore, a strategy that preserves the tumor suppressive isoforms and targets the oncogenic 
isoforms should be considered. However, use of an in vivo model to further assess the role of 
the long non-coding variants will be an important step in understanding the functional 
implications of the long non-coding expression of BMP-2 and of other BMP superfamily 
members. 
To extend our understanding of the long non-coding BMP-2 variant on tumorigenicity 
and metastasis, we will perform an orthotopic implantation of VC, lnc expressing, or KD HupT3 
cells into the pancreas of athymic nude mice. Using an orthotopic mouse model, we can begin 
to assess how the expression or loss of the non-coding BMP-2 variant may affect the relative 
incidence of metastasis as these cells must invade surrounding tissue, extravasate/intravasate , 
disseminate, and colonize a new site. Given our current understanding of the influence of the 
long non-coding BMP-2 variant, we expect expression or knockdown to have a significant 
impact on the metastatic potential of these cells. 
While cancer is most frequently associated with unrestrained growth and metastatic 
spread, neurodegeneration and cell death associated with AD provides a striking contrast. 
Despite the apparent dissimilarities, the molecular dysregulation of the mitogen and morphogen 
signaling axis may be an underlying source and common thread between these two diseases. 
The extracellular accumulation of amyloid beta peptide and formation of neurotic plaques are 
pathognomonic features most associated with this illness. However, recent findings have 
suggested the intracellular accumulation of the amyloid beta peptide to precede extracellular 
accumulation. Mitogenic and morphogenetic homeostasis are critical mediators of neuronal 
viability and programmed cells death. We have employed an in vitro model to understand the 
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fundamental influence that intracellular amyloid beta (iAβ) may have on the mitogen and 
morphogen signaling axis.  
To do this, we first ectopically expressed the iAβ in HEK293 cells to understand the 
basic functional and mechanistic effects of iAβ expression. These preliminary experiments 
revealed an iAβ mediated decrease in EGF dependent ERK 1/2 phosphorylation. Furthermore, 
we found iAβ expression led to a significant increase in the BMP-2 mediated Smad 1/5/8 
phosphorylation. Thus, the observed changes in signal transduction were not a global response, 
but had contrasting and pathway specific effects. We further examined the influence of iAβ 
expression on EGFR abundance and found that iAβ did not alter the basal abundance of these 
proteins. However, upon EGF stimulation there was a significant decrease in the presence of 
total and phospho-EGFR levels in the context of iAβ expression. These findings suggest that 
iAβ expression may be negatively influencing the stability of the receptor perhaps through 
disruption endocytic recycling.  
Therefore, to rescue the diminished mitogen signaling activity we identified a strategy 
that could amplify mitogen signaling in a manner that did not rely on absolute concentrations of 
extracellular ligand or receptor. To do this we used PLX4032, which at low concentrations, has 
been shown to lead to the dimerization of B-Raf and C-Raf and subsequently enhance 
phospho-ERK 1/2 levels. Interestingly, pretreatment with PLX4032 restored the ERK 1/2 
phosphorylation in iAβ expressing cells.  
With a fundamental understanding of how iAβ expression may influence mitogen and 
morphogen signaling pathways, we sought to extend our understanding by using primary rat 
hippocampal neurons. These cells were matured in vitro to an extent that would mirror the 
physiological features observed in a mature brain. Subsequently, the cells were transduced with 
iAβ and their BDNF dependent induction of ERK 1/2 was assessed. Using this system to mirror 
the in vivo expression of iAβ we observed a similar and statistically significant decrease in 
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induction of ERK 1/2 activity upon iAβ expression. Furthermore, we successfully employed 
PLX4032 to rescue the iAβ mediated decrease in BDNF dependent induction of ERK 1/2 
phosphorylation.  
While these observations will undoubtedly improve our understanding the 
pathophysiological role of iAβ expression in the context of AD, additional studies will be 
necessary to understand the role of iAβ in an in vivo setting. Currently, there are no genetically 
engineered animal models that strictly recapitulate the intracellular localization of amyloid beta. 
Thus, to address the pathological effects on neuronal viability and cognitive function, the 
generation of an iAβ1-42 transgenic model will be paramount to furthering understanding of the 
consequences of iAβ1-42 expression. Moreover, an in vivo model is a critical component in 
comprehensively evaluating PLX4032 and other strategies for circumventing the effects of iAβ1-
42 expression. Indeed, the greatest hope for addressing this illness is an early diagnosis and 
prevention of subsequent progression of the disease. Thus, the tendency for iAβ to be 
expressed early, our observations regarding it function and mechanism, and a potential strategy 
for attenuating the pathophysiological role of this isoform may prove invaluable as we consider 
therapeutic strategies to thwart the progression this disease. 
The coincidental study of both pancreatic cancer and Alzheimer’s disease may not have 
an immediately obvious relationship, thus I would like to provide a brief reflection upon the 
course of this investigation and how our study of these very different pathologies became 
manifested. Our original application of MCOPA bioinformatics analysis was intended to identify 
structural gene rearrangements in pancreatic cancer. A similar and successful application of this 
approach had been previously employed in the nomination of gene rearrangements in prostate 
cancer involving the TMPRSS2 and ERG gene fusions (MacDonald, Ghosh 2006). In a similar 
manner, we had hoped to identify structural rearrangements (gene fusions) that may participate 
in driving pancreatic cancer. Upon screening our MCOPA nominated genes for the presence of 
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gene fusions, we found BMP-2 to have lost region-specific expression in a pattern that was 
consistent with that observed upon gene rearrangement. However, further investigation 
revealed the change in expression within a specific region of the BMP-2 gene transcript was a 
consequence of alterative spicing.  
 Alternative splicing of BMP-2 was a compelling observation that harbored several 
intriguing and important implications in bone morphogenetic signaling. As described, 
investigation of these coding and non-coding variants has revealed them to be important 
contributors of the pleiotropic properties associated with expression of BMP-2 in PC. Our 
subsequent characterization of the intracellular coding BSV showed it to be preferentially 
degraded by the autophagy lysosome pathway opposed to by the ubiquitin proteasome system. 
Given the tendency of the amyloid beta peptide to generate aggregates, propensity for amyloid 
beta intracellular localization, and for intracellular aggregates to be cleared by the ALP pathway, 
we sought to understand whether their coincidental turnover may be important in neuronal 
MAPK and morphogen signaling homeostasis in the context of Alzheimer’s disease. Although 
the second part of my dissertation demonstrated an intracellular amyloid beta mediated 
increase in BMP-2 dependent Smad 1\5\8 phosphorylation, we were not able to assess the 
extent to which the intracellular coding BSV may influence this pathway. Our examination of the 
morphogenic signaling pathways in PC suggests a significant degree of coordination between 
the various elements involved in BMP-2 dependent signaling and may have noteworthy 
implications in the strength and duration of signaling in neuronal cells. Going forward, 
understanding the influence of intracellular amyloid beta and intracellular isoforms involved in 
morphogen signaling may be important aspects of this pathological axis.  
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